

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

## OVERVIEW

### BACKGROUND AND DATA SOURCES

There are three measures that are commonly used to assess the impact of cancer in the general population. The **incidence rate** is the number of new cases per year per 100,000 persons. The **mortality rate** is the number of deaths per year per 100,000 persons. The **survival rate** is the proportion of patients alive at some point subsequent to the diagnosis of their cancer. All three measures are employed in this report. The Surveillance, Epidemiology, and End Results (**SEER**) Program (<http://seer.cancer.gov>) — based within the Surveillance Research Program (**SRP**) at the National Cancer Institute (**NCI**) — collects incidence and survival data for all areas that participate in the Program. The National Center for Health Statistics (**NCHS**) provides mortality data for the entire United States (**US**). All incidence and mortality rates in this report are age-adjusted (see below) to the 2000 US standard million population (see Appendix) unless otherwise specified. Age adjustment minimizes the effect of a difference in age distributions when comparing rates. Data are presented for a wide spectrum of cancers.

The annual *SEER Cancer Statistics Review (CSR)*, containing the most recent incidence, mortality, and survival statistics, is published by the Cancer Statistics Branch of the NCI. The scope and purpose of the CSR follow a report to the Senate Appropriations Committee (Breslow, 1988), which recommended that a broad profile of cancer be presented regularly to the American public. This CSR includes incidence, mortality, and survival data from 1975 through 2000, the most recent year for which data are available. (Incidence data for 2000 may not be complete. Therefore, *exercise caution when comparing rates for 2000 with those for previous years.*) Most of the rates in this publication have been age-adjusted to the 2000 US standard million population. Some previous publications have used the 1970 US standard million population. Therefore, this publication can not be compared to those publications. This change conforms to a new federal policy for reporting disease rates and it allows for the age-adjusted rate to more accurately reflect the current age distribution and burden of cancer.

Since 1996, the CSR has also been available (in .pdf format) at <http://seer.cancer.gov/csr>. The website allows timelier distribution of the CSR. Additional SEER data can be obtained via **FastStats** (<http://seer.cancer.gov>) or **CanQues**, an interactive system at <http://seer.cancer.gov/query>, which allows the user to access over 10,000,000 cancer statistics. The SEER public-use file with **SEER\*Stat** software can be used over the internet or the user can order a CD-ROM at <http://seer.cancer.gov/publicdata>. **SEER\*Stat** provides a user-friendly PC desktop system for the production of a myriad of cancer statistics, such as incidence rates and survival rates, for various demographic and medical input variables. The SEER public-use data file contains information on over 3,400,000 tumors with no personal identifiers.

### THE SEER PROGRAM

The National Cancer Act of 1971 mandated the collection, analysis, and dissemination of data useful in the prevention, diagnosis, and treatment of cancer. This mandate led to the establishment of the SEER Program. A continuing project of the NCI, the population-based cancer registries participating in the SEER Program routinely collect data on all cancers occurring in residents of the participating areas. Trends in cancer incidence and patient survival in the US are derived from this database.

The SEER Program is a sequel to two earlier NCI programs — the End Results Program and the Third National Cancer Survey. The initial SEER reporting areas were the States of Connecticut, Iowa, New Mexico, Utah, and Hawaii; the metropolitan areas of Detroit, Michigan, and San Francisco-Oakland, California; and the Commonwealth of Puerto Rico. Case ascertainment began with January 1, 1973, diagnoses.

In 1974-1975, the program was expanded to include the metropolitan area of New Orleans, Louisiana, the thirteen-county Seattle-Puget Sound area in the State of Washington, and the metropolitan area of Atlanta, Georgia. New Orleans participated in the program only through the 1977 data collection year. In 1978, ten predominantly black rural counties in Georgia were added. American Indian residents of

Arizona were added in 1980. In 1983, four counties in New Jersey were added with coverage retrospective to 1979. New Jersey and Puerto Rico participated in the program until the end of the 1989 reporting year. The National Cancer Institute also began funding a cancer registry that, with technical assistance from SEER, collects information on cancer cases among Alaska Native populations residing in Alaska. In 1992, the SEER Program was expanded to increase coverage of minority populations, especially Hispanics, by adding Los Angeles County and four counties in the San Jose-Monterey area south of San Francisco. In 2002, the SEER Program expanded coverage to include Kentucky and Greater California (the counties of California that were not already covered by SEER). Also in 2002, New Jersey and Louisiana became SEER participants again.

The long-term incidence trends and survival data for this report are from five states — Connecticut, Hawaii, Iowa, New Mexico, and Utah — and four metropolitan areas — Detroit, Atlanta, San Francisco-Oakland, and Seattle-Puget Sound (Fig. I-1). Additional tables show more recent incidence rates and trends for the SEER 12 areas (the 9 areas above plus Los Angeles, San Jose-Monterey, and the Alaska Native Registry) since 1992.

The participating regions were selected principally for their ability to operate and maintain a population-based cancer reporting system and for their epidemiologically significant population subgroups. With respect to selected demographic and epidemiologic factors, they are when combined a reasonably representative subset of the US population. Data from the 9 or 12 SEER geographic areas used in this report represent, respectively, approximately 9 or 14 percent of the US population. By the end of the 2000 diagnosis year, the database contained information on over 3,400,000 cases diagnosed since 1973. Over 170,000 new cases are added annually.

The goals of the SEER Program are:

- (1) to assemble and report, on a periodic basis, estimates of cancer incidence and mortality in the US;
- (2) to monitor annual cancer incidence trends to identify unusual changes in specific forms of cancer occurring in population subgroups defined by geographic and demographic characteristics;
- (3) to provide continuing information on trends over time in the extent of disease at diagnosis, trends in therapy, and associated changes in patient survival; and
- (4) to promote studies designed to identify factors amenable to cancer control interventions, such as: (a) environmental, occupational, socioeconomic, dietary, and health-related exposures; (b) screening practices, early detection and treatment; and (c) determinants of the length and quality of patient survival.

**Incidence and survival data:** The SEER Program contracts with nonprofit, medically-oriented organizations having statutory responsibility for registering diagnoses of cancer among residents of their respective geographic coverage areas. Each SEER contractor:

- (1) maintains a cancer information reporting system;
- (2) abstracts records for *resident* cancer patients seen in every hospital both inside and outside the coverage area;
- (3) abstracts all death certificates of *residents* (dying both inside and outside the coverage area) on which cancer is listed as a cause of death;
- (4) ensures complete ascertainment of cases by searching records of private laboratories, radiotherapy units, nursing homes, and other health services units that provide diagnostic service;
- (5) registers all in situ and malignant neoplasms (with the exceptions of certain histologies for cancer of the skin and (beginning in 1996) in situ neoplasms of the cervix uteri);
- (6) records data on all newly diagnosed cancers, including selected patient demographics, primary site, morphology, diagnostic confirmation, extent of disease, and first course of cancer-directed therapy;
- (7) provides active follow-up on all living patients (except for those with in situ cancer of the cervix uteri);
- (8) maintains confidentiality of patient records;
- (9) semiannually submits electronically to NCI data on all reportable diagnoses of cancer made in residents of the coverage area.

For 1992 to 2000 diagnoses, the SEER program codes site and histology by the *International Classification of Diseases for Oncology*, second edition (ICD-O-2) (Percy, Van Holten, & Muir, 1990). All cases before 1992 were machine-converted to ICD-O-2. Beginning with 2001 diagnoses, cases will be coded according to the third edition (ICD-O-3) (Fritz et al., 2000). The primary site groupings used for incidence are found in the Appendix. Changes were made to the site recode for ICD-O-2 for comparability with cases coded to ICD-O-3. Follow-up rates are also in the Appendix.

**Mortality data:** The SEER Program annually obtains from the NCHS a public-use file containing information on all deaths occurring in the US by calendar year. Information on each death includes age at death, sex, geographic area of residence, and underlying and contributing causes of death. For this publication, only the underlying cause of death is used in the calculation of mortality rates. Cause of death before 1999 was coded according to ICD-9; beginning with deaths in 1999, ICD-10 was used. Mortality rates for the SEER geographic areas, for each state, and for the entire US are obtained from these data. A list of the mortality site groupings used in this publication is in the Appendix and reflects updates made in 2003.

**Numbers of estimated cancers and deaths in 2003:** The SEER Program has obtained from the American Cancer Society (ACS) projections of the numbers of cancer cases and cancer deaths in the US in 2003. The ACS projects incidence in 2003 based on incidence rates from SEER for 1979-99 to the 2003 estimated US population (Jemal et al., 2003).

**Population data:** The county population estimates implemented in the NCI SEER\*Stat software for the calculation of cancer incidence and mortality rates are available at <http://seer.cancer.gov/popdata/download.html>. They represent a modification of the annual time series of county population estimates (by age, sex, race, and Hispanic origin) produced by the Population Estimates Program of the Bureau of the Census with support from the NCI through an interagency agreement. The Census Bureau's population estimates are available on their Web site, <http://leire.census.gov/popest/data/counties.php>. The procedures implemented by the Census Bureau in producing their county estimates are documented at [http://www.census.gov/population/estimates/county/casrh\\_doc.txt](http://www.census.gov/population/estimates/county/casrh_doc.txt). Please refer to <http://seer.cancer.gov/popdata/methods.pdf> for specific documentation regarding modifications made by the NCI to the Census Bureau estimates. The following summarizes these modifications.

The initial modification affects only population estimates for the State of Hawaii. The Epidemiology Program of the Hawaii Cancer Research Center has developed its own set of population estimates, based on sample survey data collected by the Hawaii Department of Health. This effort grew out of a concern that the native Hawaiian population has been vastly undercounted in previous censuses. The "Hawaii-adjustment" to the BOC estimates has the net result of reducing the estimated white population and increasing the Asian and Pacific Islander population for the state. The Bureau of the Census estimates for the total population, black population, and American Indian and Alaska Native populations in Hawaii are unaffected.

An additional modification to the Census Bureau estimates was recently implemented in order to meet requirements for age-adjustment according to the year 2000 US population standard. Population estimates for two new age groups (less-than-one-year-olds and one-to-four-year-olds) were created for the 1969-89 estimates and for the 1990-2000 estimates.

The population estimates now incorporate bridged single-race estimates for 2000, that are derived from the original multiple-race categories in the 2000 Census (as specified in the 1997 Office of Management and Budget standards for the collection of data on race and ethnicity). These bridged estimates are consistent with the four race groups enumerated in the 1990 Census (White; Black; American Indian, Eskimo, and Aleut; and Asian and Pacific Islander) and were produced under a collaborative arrangement between the National Center for Health Statistics and the Census Bureau. The bridged single-race estimates and a description of the methodology used to develop them appears on the NCHS website <http://www.cdc.gov/nchs/about/major/dvs/popbridge/popbridge.htm>.

In addition, a revised set of 1990-99, and new 2000, estimates for <1 year old, 1-4, 5-9, 10-14, ... , 80-84, and 85+ age county populations was recently obtained by NCI from the Census Bureau through an interagency agreement. This file contains populations by year, county, race, Hispanic origin, sex, and age. The race groups included in the Census estimates are White, Black, American Indian/Eskimo/Aleut, and Asian/Pacific Islander. Population records were created for 19 age groups (<1, 1-4, 5-9, ... , 85+) for White (total), Hispanic White, Non-Hispanic White, Black, American Indian/Eskimo/Aleut, and Asian/Pacific Islander. The methodology implemented by the Census Bureau to develop these county estimates is comparable to that used to produce national and state 1990-2000 intercensal estimates and is described on the Census Bureau's website <http://eire.census.gov/popest/topics/methodology/usintercensal.php>. Thus, intercensal (between 1990 and 2000) statistics published here may differ from those published in previous editions of the CSR.

## DEFINITIONS

Several technical terms are used in presenting the data in this report. Their definitions are presented here to clarify them for the reader.

**Incidence rate:** The cancer incidence rate is the number of new cancers of a specific site/type occurring in a specified population during a year, usually expressed as the number of cancers per 100,000 population at risk. That is,

$$\text{Incidence rate} = (\text{New cancers} / \text{Population}) \times 100,000.$$

The *numerator* of the incidence rate is the number of new cancers; the *denominator* of the incidence rate is the size of the population. The number of new cancers may include multiple primary cancers occurring in one patient. *The population used depends on the rate to be calculated.* For cancer sites that occur in only one sex, the sex-specific population (e.g., females for cervical cancer) is used.

The incidence rate can be computed for a given type of cancer or for all cancers combined. Except for 5-year age-specific rates, all incidence rates are *age-adjusted* (see below) to the 2000 US standard million population (or, where appropriate, to the world standard million population). (In some previous editions of the CSR, the 1970 US standard million population was used; therefore, incidence rates in this edition can not be compared to rates published in those editions.) Incidence rates are for *invasive cancer only*, unless otherwise specified. (Exceptions are the incidence rate for cancer of the urinary bladder (there both in situ and invasive cancers are counted) and breast cancer in situ, which is shown separately.)

**Mortality rate:** The cancer mortality rate is the number of deaths with cancer given as the underlying cause of death occurring in a specified population during a year, usually expressed as the number of deaths due to cancer per 100,000 population. That is,

$$\text{Mortality Rate} = (\text{Cancer Deaths} / \text{Population}) \times 100,000.$$

The *numerator* of the mortality rate is the number of deaths; the *denominator* of the mortality rate is the size of the population. As with the incidence rate, *the population used depends on the rate to be calculated.* The mortality rate can be computed for a given cancer site or for all cancers combined. Except for 5-year age-specific rates, all mortality rates are *age-adjusted* (see below) to the 2000 US standard million population (or, where appropriate, to the world standard million population). (In some previous editions of the CSR, the 1970 US standard million population was used; therefore, mortality rates in this edition can not be compared to rates published in those editions.)

**Standard million population:** A **standard population** for a geographic area, such as the US or the world, is a table giving the proportions of the population falling into the age groups 0, 1-4, 5-9, ..., 80-84, and 85+. A **standard million population** for a geographic area is a table giving the number of persons in each age group 0, 1-4, ... , 85+ out of a theoretical cohort of 1,000,000 persons that is distributed by age in the same proportions as the population. Table A-7 shows the US 2000 and world standard million populations. This publication does not use the new world standard million population used in some World Health Organization mortality publications.

**Age-adjusted rate:** An age-adjusted incidence or mortality rate is a weighted average of the age-specific incidence or mortality rates, where the weights are the proportions of persons in the corresponding age groups of a standard million population. The potential confounding effect of age is reduced when comparing age-adjusted rates computed using the same standard million population. For this report, the 2000 US standard million population and the world standard million population are used as the weights in computing age-adjusted rates, unless otherwise noted.

**Percent change:** The percent change (PC) in a statistic over a given time interval is

$$\text{Percent change} = (\text{Final value} - \text{Initial value}) / \text{Initial value} * 100.$$

(In this report, the initial year is usually 1975 and the final year is usually 2000.) A positive PC corresponds to an increasing trend, a negative PC to a decreasing trend.

**Annual percent change:** The annual percent change (APC) is calculated by first fitting a regression line to the natural logarithm of the rates ( $r$ ) using calendar year ( $x$ ) as a regressor variable. In this report the method of *weighted least squares* is used to calculate the regression equation. If  $\ln(r) = mx + b$  is the resulting regression equation (with slope  $m$ ), then  $APC = 100(e^m - 1)$ . A positive APC corresponds to an increasing trend, a negative APC to a decreasing trend.

Because the methods used in their calculation are mathematically different, *the signs of the PC and the APC for a given statistic and time interval may differ*, as occurs in a few of the tables presented. That is, one of these statistics may show an increasing trend, the other a decreasing trend.

Testing the hypothesis that the actual mean annual percent change is 0 is equivalent to testing the hypothesis that the theoretical slope estimated by the slope  $m$  of the line representing the equation  $\ln(r) = mx + b$  is 0. The latter hypothesis is tested using the  $t$  distribution of  $m / SE_m$  with  $n - 2$  degrees of freedom. The standard error of  $m$ ,  $SE_m$ , is obtained from the fit of the regression (Kleinbaum et al., 1988). (This calculation assumes that the rates increased or decreased at a constant rate over the entire calendar year interval; the validity of this assumption was not assessed.) In those few instances where at least one of the rates was 0, the linear regression was not calculated.

**Life table:** A table for a given population listing, for each sex and each age from 0 to 120, how many members die at that age and how many survive one more year.

**Observed survival rate:** The observed survival rate represents the proportion of cancer patients surviving for a specified time interval after diagnosis. Note that some of those not surviving died of the given cancer and some died of other causes.

**Relative survival rate:** The relative survival rate is calculated using a procedure (Ederer et al., 1961) whereby the observed survival rate is adjusted for expected mortality. The relative survival rate approximates the likelihood that a patient will not die from causes associated specifically with the given cancer before some specified time after diagnosis. It is always larger than the observed survival rate for the same group of patients.

**Standard error:** The standard error of a rate is a measure of the sampling variability of the rate.

**Person-years of life lost:** The person-years of life lost (PYLL) is calculated as follows: For each individual who dies of the cancer of interest, the number of years of expected additional life for an average person of that age and sex is obtained from life tables for the US population (available from the NCHS). The PYLL in the general population associated with a particular cancer is simply the sum of this expectation over all those individuals who died of that cancer in a particular year.

**Average years of life lost:** The average years of life lost (AYLL) associated with a particular cancer is the PYLL associated with that cancer in the general population divided by the number of deaths from that cancer in the general population in a specific year.

**Prevalence:** Prevalence is defined as the number or percent of people alive on a certain date in a population who previously had a diagnosis of the disease. It includes new (incidence) and pre-existing cases and is a function of both past incidence and survival.

**Stage of disease at diagnosis:** Extent of disease information determines stage of disease at diagnosis. The historical stage presented has four levels. An invasive neoplasm confined entirely to the organ of origin is said to be **localized**. A neoplasm that has extended beyond the limits of the organ of origin, either directly into surrounding organs or tissues or into regional lymph nodes, is said to be **regional**. A neoplasm that has spread to parts of the body remote from the primary tumor, either by direct extension or by discontinuous metastasis, is said to be **distant**. When information is not sufficient to assign a stage, a neoplasm is said to be **unstaged**. In situ tumors (except those of the cervix uteri) are also collected by SEER but generally are not published in this series. For some cancers and diagnosis years, the extent of disease information can also be converted to Stages 0-IV as defined by the American Joint Committee on Cancer (Beahrs et al., 1988).

## SUMMARY TABLES

While there are detailed tables in separate sections for each of the major cancer sites, information on some rare cancers can be found in the summary tables of section I. For a detailed list of primary sites, the summary tables provide incidence and mortality rates for the most recent 5-year period, trends — percent change (PC) and annual percent change (APC) — from 1975 to the most recent year, median age at diagnosis, median age at death, and survival rates. The information is provided by race (all races, whites, blacks) and by sex.

## LONG-TERM TRENDS, 1950-2000

Trends in cancer mortality from 1950 to 2000 are summarized by age both for all cancers combined and for lung and bronchus cancer (Table I-2). These mortality data are based on experience in the entire US.

Summaries of long-term trends in cancer incidence, mortality, and survival are outlined in Table I-3. The first two columns of the table show the estimated number of new cancers and the reported number of cancer deaths for 2000; the next four columns show incidence and mortality changes from 1950 to 2000. Both the percent change (PC) and the annual percent change (APC) for incidence are based on data from the five geographic areas for which data are available for each of three time periods: around 1950, 1969-71, and 1975-2000. Due to the limited availability of incidence data from the early time periods and the change in the composition of the nonwhite population over time, the incidence trends are presented for whites only. The estimates for children are for children of all races in Connecticut only. Mortality data are for the entire US; they are for whites only in order to be comparable to the incidence data. The last two columns display 5-year relative survival figures for patients diagnosed during two time intervals, 1950-54 and a recent time period; the figures are based on information from the End Results Program for 1950-54 and SEER for the recent time period.

*Use caution when interpreting these statistics. Evaluating trends over a long period of time may hide recent changes in the trends.*

## YEARS OF LIFE LOST DUE TO PREMATURE DEATH FROM VARIOUS CAUSES

Mortality rates alone give an incomplete picture of the burden deaths impose on the population. Another measure, which adds a different dimension, is the years of life lost due to premature death. This shows the extent to which life is cut short by a particular cause or disease.

This measure is estimated by linking life table data to each death of a person of given age and sex. The life table permits a determination of the number of additional years an average person of that age and sex would be expected to live. In this report, the age groups used in the calculation were 1-year intervals. These remaining years of life left are summed over all deaths due to a particular cause, yielding the

estimate of the number of person-years of life lost (PYLL). The average years of life lost (AYLL) is obtained by dividing the PYLL by the number of deaths. Both of these measures can be calculated for any cause of death.

## CANCER PREVALENCE

Prevalence is defined as the number or percent of people alive on a certain date in a population who previously had a diagnosis of the disease. It includes new (incidence) and pre-existing cases and is a function of both past incidence and survival. Tables on prevalence are not shown in the overview this year. Instead, there is a special section devoted to prevalence which includes prevalence estimates and a discussion of statistical methods used to calculate prevalence.

**Limited-duration prevalence** was calculated using the counting method. This method uses registry data to compute the proportion of the population alive on a specified day who were diagnosed within a specified period prior to the prevalence date. To adjust prevalence proportions for cases lost to follow-up, survival functions stratified by age (<60, 60-69, 70+), sex, cancer site, year of diagnosis (1975-79, 1980-84, 1985-89, 1990-94, 1995-99), and race were calculated. Since some people in the registry are lost to follow-up, for each individual lost to follow-up, a probability of being alive at the prevalence date is estimated from the appropriate survival function (based on age, sex, cancer site, year of diagnosis, and race), conditional on being alive at the time of loss to follow-up.

Only the first malignant tumor per person was used to compute prevalence estimates. Because SEER has available information for the various racial/ethnic groups for different numbers of years, different years and registries were used to estimate limited-duration prevalence. Cases from 1975 through 1999 from the SEER 9 registries were used to calculate 25-year prevalence proportions for all races combined, whites, and blacks. Cases diagnosed from 1990 through 1999 from the SEER 11 registries were used to calculate 10-year prevalence proportions for Asian/Pacific Islanders; cases diagnosed from 1990 through 1999 from the SEER 11 excluding Hawaii and Detroit were used to calculate 10-year prevalence proportions for Hispanics.

**Complete prevalence** is an estimate of the proportion of previously diagnosed cases alive on a specified date, no matter how long ago that diagnosis was. It was estimated for all races, whites, and blacks by applying the completeness index method (Capocaccia & De Angelis, 1997; Merrill et al., 2000; Mariotto et al., 2002) to 25-year limited-duration prevalence. Validation of the completeness index for all races and for whites was made by using data from the Connecticut Tumor Registry (CTR) from 1940; for blacks, SEER 9 data from 1975 were used. (Identification of blacks is not possible in the CTR prior to 1970.) To validate the completeness index for blacks, we have compared the performance of the method to obtain 24-year prevalence from 10-year limited-duration prevalence. For all races combined and for whites, in cases where the validation indicated some lack of fit of the model, an approximation to the completeness index was derived from the CTR data. If there was a lack of fit for blacks, no estimate of complete prevalence was reported. Complete prevalence for Asian/Pacific Islanders and Hispanics is not available at this time.

The US cancer prevalence counts as of January 1, 2000, were estimated by multiplying the SEER age- and race-specific prevalence proportions by the corresponding January 1, 2000, US population estimates based on the average of 1999 and 2000 population estimates from the US Bureau of the Census. US cancer prevalence counts for all races were estimated by summing the US estimated counts for whites/unknown, blacks, and other races. For Hispanics, the estimates for Hispanics of white or unknown race and for Hispanic others were summed. Prior to this report, prevalence counts for all races combined were estimated by multiplying the all-race age-specific proportions by the corresponding US populations. The new computation improves on what was done previously because it adjusts for racial differences between SEER and the US.

The total number of persons alive on January 1, 2000, in the U.S. who had a diagnosis of cancer is now estimated to be 9,555,312. Compared with last year's prevalence estimate of 8,928,058 persons, this year's 2000 estimate represents an increase of 627,254 cases. A portion of this increase is due to



changes in population counts for the US and SEER areas, based on the 2000 Census and closure procedures to estimate the 1990-1999 intercensal populations. Another portion is due to improvements in the methodology related to adjustments for racial differences between the US and SEER. The final portion (estimated to be at least half the increase) is due to increases in incidence, improvements in survival, and the increase and aging of the US population.

Limited-duration prevalence proportions by age at prevalence are not shown for childhood cancers (diagnosis before age 20) since many of these estimates are not informative. (For example, the number of people diagnosed with childhood cancers in the last 25 years and who are currently age 50-59 is zero by definition.) While it is of interest to estimate the total number of Americans currently alive who were diagnosed with a childhood cancer, the limitations of the duration of the SEER cancer registries requires that this be estimated using statistical modeling. (This work is in progress.)

For more details on available prevalence estimates, see <http://srab.cancer.gov/prevalence/index.html>.

## PROBABILITY OF BEING DIAGNOSED WITH OR DYING FROM CANCER

Each site-specific section of the book contains a table showing the probability (expressed as a percent) of a person of a specified race, sex, and age (0, 10, 20, 30, 40, 50, or 60) being diagnosed with the specified cancer within the next 10, 20, or 30 years or within their remaining lifetime. Lifetime risks of being diagnosed with cancer and lifetime risks of dying from cancer also appear (as percents) in each table. There are summary tables of lifetime risk in the overview.

**Lifetime and interval risks of being diagnosed with cancer:** The probability of being diagnosed with cancer is computed by applying cross-sectional age-specific 1998-2000 incidence rates from the 12 SEER areas and mortality rates from the entire US to a hypothetical cohort of 10,000,000 live births. This cohort is considered to be at risk for two mutually exclusive events: (1) developing the specified cancer, and (2) dying of other causes without developing the specified cancer. Using these two types of events, a standard **multiple decrement life table** (with 20 age groups from 0-4 to 90-94 and 95+) is derived. For each age interval, the number alive and free of the specified cancer at the beginning of the interval is decremented by the number who develop the specified cancer and the number who die of other causes. The lifetime risk of being diagnosed with the specified cancer is derived by summing all cancer cases from age 0-4 through age 95+ and dividing by 10,000,000. This calculation does not assume an individual lives to any particular age; rather, it is the sum over all age intervals of the probability of living to the beginning of that interval without developing the given cancer times the probability of developing the cancer in that interval. The probability of developing cancer during any time period (e.g., within 10 years of a specific age, say 50) is calculated by adding up all the cancers in the life table over the specified age range and dividing by the number of individuals alive and free of the specified cancer at the beginning of the period (Feuer et al., 1992; Feuer et al., 1993). To improve the precision of the calculations, rates were calculated for the age groups 85-89, 90-94, and 95+. The BOC provided populations for these age groups for 1990 to 1999; for 2000, the populations of these age groups were estimated by multiplying the corresponding proportions for 1999 by the 2000 total population.

**Lifetime risk of dying from cancer:** The lifetime risk of dying from a specified cancer is derived using a standard multiple decrement life table (Elandt-Johnson & Johnson, 1980). For each age, the risks of dying of the specified cancer and of all other causes are calculated, based on mortality data from the entire United States.

## U.S. CANCER MORTALITY RATES BY STATE

Each cancer-site-specific section of the book presents, for all 50 states and the District of Columbia, average annual mortality rates for the most recent 5-year period for all persons, males only, and females only. The rates are per 100,000 persons; they are age-adjusted to the US 2000 standard million population. (In previous editions of the CSR, the 1970 US standard million population was used; therefore, mortality rates in this edition differ from those in earlier editions.) The five states with the highest rates and the five states with the lowest rates are identified. The states are also ranked from

highest rate to lowest rate for each of the cancers for which rates are reported.

The **percent difference (PD)** between a state rate and the rate for the total US is given by the formula:

$$PD = [(State\ rate - Total\ US\ rate) / Total\ US\ rate] \times 100.$$

The **standard error** for each age-adjusted state rate is calculated, based on the assumptions that (1) for each age-specific rate, the number of deaths is a Poisson random variable (Keyfitz, 1966) and (2) the variance of the age-adjusted rate is a linear combination of the variances of the age-specific rates (Snedecor & Cochran, 1980; pp. 188-9).

The **standard error of the difference ( $SE_d$ )** between a state rate and the total US rate is given by the formula

$$SE_d = \sqrt{SE_s^2 + SE_u^2},$$

where  $SE_s$  and  $SE_u$  are the standard errors of a state rate and of the total US rate, respectively. The variance of each rate (i.e., the square of the standard error) is based on the Poisson assumption. The standard error does not represent the total error that may be present in the age-adjusted rate; it is merely the square root of the variance associated with the rates. In addition to this variance, there also exist potential biases and errors in the measurement of the rate that are difficult to assess accurately and probably impact differently on the error calculations for different states.

The difference between each age-adjusted state rate and the age-adjusted US rate is tested for statistical significance (see below) by calculating a Z (standard normal) statistic from the formula:

$$Z = (State\ rate - Total\ US\ rate) / SE_d$$

Although the rates being compared are not independent because each state is part of the US, this doesn't substantially affect the statistical test because each state represents a small proportion of the total US. There is also an adjustment for multiple comparisons; see below under "Statistical Significance."

## MEASUREMENT ERRORS

Errors in the estimation of death rates can occur in either the numerator (the number of reported deaths) or the denominator (the size of the population). One possible source of numerator error is underregistration of deaths. Although investigation by the National Center for Health Statistics indicates that over 99% of all deaths in the US are registered, little is known about the possible existence of any differences in death registration by geographic area, age, sex, or race.

Numerator error also can occur due to misclassifications, especially of race, ethnicity, or cause of death. Research indicates that, for infant mortality, misclassification is highest for races other than white or black (Hahn et al., 1992). The true extent of racial or ethnic misclassifications in death certificate coding remains unknown.

In coding overall cancer mortality, misclassifications of cause of death would occur when either the true cause of death was cancer while a cause other than cancer was coded, or vice versa. Even if a death is correctly attributed to cancer, the primary cancer may be incorrectly identified. It is already known, for example, that this is a problem with primary liver cancer (Percy, Ries, & Van Holten, 1990).

Denominator errors arise through under- and overenumeration in the decennial census, which is the basis of intercensal population estimates and population projections. To the extent that any over- or undercount is substantial and variable among subgroups or geographic areas, it may have important consequences on calculated death rate statistics. The effect of an *undercount* of population is that it decreases the denominator, leading to an *overestimate* of the rate. Conversely, an *overcount* of population would result in an *underestimate* of the rate.

In 1980, underenumeration varied by age group, with the greatest difference found for those 80 and older, who were undercounted by about 5% (US Bureau of the Census, 1986). All other age groups were either over- or undercounted by less than 3%. For race-sex-age groups, the coverage was lowest for black

males aged 40-49, who were undercounted by 19%. It is thought that no improvement was achieved with the 1990 census; in some instances, underenumeration may have been worse than in 1980.

As described above, a revised set of intercensal (between 1990 and 2000) county populations was recently obtained by NCI from the Census Bureau through an interagency agreement. Thus, intercensal statistics published here may differ from those published in previous editions of the CSR.

Any of these errors alters the count in either the numerator or the denominator, which in turn affects the calculated rate. Since the types of error encountered may differ by type of cancer, age group, race, sex, or even state, their impact is difficult to ascertain. *Use caution when dealing with those areas where potential problems may be present.*

## JOINPOINT REGRESSION ANALYSIS OF CANCER TRENDS

A recent advance in the presentation of cancer trends is the use of joinpoint models (Kim et al., 2000). In past issues of the *Cancer Statistics Review*, certain time intervals (e.g., 1973-1996) were specified and the annual percent changes (APC) were computed over those intervals. The choices of where to start and where to end an interval were arbitrary and sometimes did not give an accurate picture of the trend for a given cancer site. For example, the rates might be increasing and decreasing in different parts of the same interval. For some sites, increases occurred in the earlier years, followed by declines in more recent years.

To achieve greater descriptive accuracy, the computer now statistically finds the number and location of places where a trend changes. The point (in time) where a trend changes is called a **joinpoint**. Trends may change in different ways at a joinpoint: from up to down, from down to up, from up to up at a different rate, or from down to down at a different rate. In order to find the most accurate set of joinpoints with corresponding fixed-rate intervals, we use a **joinpoint regression model**. Joinpoint regression models on the natural logarithms of the rates describe the trends by a sequence of connected straight line segments. Adjacent segments are connected at a joinpoint. Each segment has an associated APC. On a logarithmic scale, the segments are linear.

Joinpoint analysis first assumes no joinpoints are needed to describe the data accurately — i.e., the trend over the entire interval 1975-2000 does not change. Joinpoints are added in turn if they are statistically significant. Thus, in the final model, each joinpoint (up to a maximum of three) represents a significant change in trend. Smoother polynomial models may provide a good fit overall, but are less sensitive to what is occurring at the ends of the data, especially for the most recent points.

A Windows-based program, *Joinpoint*, is freely available at <http://srab.cancer.gov/joinpoint/>; it accepts data from the SEER\*Stat program. Further details on joinpoint regression may be found in a previous CSR (Ries et al., 2000) and in the cited reference.

## REPORTING DELAY

Timely and accurate calculation of cancer incidence rates is hampered by **reporting delay**, the time elapsed before a diagnosed cancer case is reported to the NCI. Currently, the NCI allows a standard delay of 22 months between the end of the diagnosis year and the time the cancers are first reported to the NCI in November, almost two years later. The data are released to the public in April of the following year. For example, cases diagnosed in 2000 were first reported to the NCI in November 2002 and released to the public in April 2003. However, in each subsequent release of the SEER data, all prior diagnosis years (e.g., diagnosis years 1999 and earlier in the 2002 submission to the NCI) are updated as either new cases are found or new information is received about previously submitted cases. The submissions for the most recent diagnosis year are, in general, about two percent below the number of cancers that will be submitted for that year in the future, although this varies by cancer site and other factors. The idea behind modeling reporting delay is *to adjust the current case count to account for anticipated future corrections (both additions and deletions) to the data*. These adjusted counts and the associated delay model are valuable in more precisely determining current cancer trends, as well as in

monitoring the timeliness of data collection -- an important aspect of quality control (Clegg et al., 2002). Reporting delay models have been previously used in the reporting of AIDS cases (Brookmeyer & Damiano, 1989; Pagano et al., 1994; Harris, 1990).

In this report, we show SEER age-adjusted incidence rates and trends, along with their calculated delay adjustments, for all cancers combined (malignant only except for urinary bladder), for female breast in situ, for urinary bladder (in situ and malignant), and for 15 malignant cancer sites: melanoma (for whites only), lung/bronchus, colon/rectum, prostate, female breast, liver and intrahepatic bile duct, pancreas, cervix uteri, ovary, kidney and renal pelvis, brain and other nervous system, non-Hodgkin lymphoma, all leukemias, esophagus, and stomach.

A delay distribution models the probability of a cancer being reported after a delay of  $d$  years ( $d = 2, 3, \dots, 21$ ). The number of cancers reported at each delay year is assumed to follow a Poisson distribution. Cases are removed as corrections to the data are made, and the probability of removing cases is modeled as a binomial distribution. To reduce the number of parameters that have to be estimated and to achieve stability in the tails of the delay distributions, an assumption is made that all cancer cases will be reported within 21 years of diagnosis.

The delay distributions were modeled as a function of covariates using a discrete-time proportional hazards model. For the models presented here the following potential covariates are included: age at diagnosis, sex, diagnosis year, delay times, and race/ethnicity. Age at diagnosis was modeled as a 3-category variable: <50, 50-64, 65+. Diagnosis year was modeled either as a continuous covariate or as categorized variables: 1981-1985, 1986-1990, or 1991-2000. Delay time  $d$  was modeled as a categorical variable in one of three ways: (1)  $d > 2$  or  $d > 3$ , (2)  $d > 2$ ,  $d > 3$ ,  $d > 4$ , or  $d > 5$ , and (3)  $d > 2$ ,  $d > 3$ , ...,  $d > 10$ . Only blacks and whites were analyzed. For melanoma, only whites were analyzed because melanoma is rare for blacks.

Maximum likelihood estimates of delay probabilities were obtained using the Newton-Raphson algorithm. For each of the cancer sites, models of many combinations of covariates were considered. We evaluated the models by fitting the models using data from each of the annual data submissions between 1983 and 2001 and then predicting the counts for the 2002 submission. For each cancer site, the model that minimized the sum of squared prediction errors was chosen as the default model. An algorithm was then used to compare the default model with competing models in order to determine a model that best balanced prediction and simplicity. The chosen model was then refitted using all data (1983-2002 submissions, 1981-2000 diagnosis years) to estimate delay distributions and calculate delay-adjusted estimates of the cancer counts.

Age-adjusted (using the 2000 US standard million population) cancer incidence rates were then calculated with and without adjusting for reporting delay. Joinpoint linear regression (Harris, 1990) was used to obtain the annual percentage changes for the 1973-2000 incidence rates for the data series with and without delay adjustment. Because the delay distribution was assumed complete after 21 years, incidence rates for diagnosis years prior to 1981 were not reporting-adjusted. In these joinpoint regression analyses, up to three joinpoints (i.e., four trend-line segments) were allowed, and these were modeled to fall at either whole years or midway between diagnosis years. Joinpoints were constrained to be at least two years away from both the beginning and the end of the data series and at least two years apart. Models were fitted using the weighted least squares (weighted by appropriate variances of age-adjusted incidence rates) option in the *Joinpoint* regression software.

Results show that adjusting for delay tends to raise cancer incidence rates in more current reporting years. While this adjustment increases the rate of change over the most recent diagnosis years, it probably will only rarely cause the detection of a new joinpoint, although this is possible. See Clegg et al. (2002) for details on the impact of reporting-delay adjustment to SEER cancer incidence rates.

## STATISTICAL SIGNIFICANCE

Errors may be made in the determination of a given statistic. In order to test whether two groups (such as the populations of a state and the entire US) have the same or different *actual* rates, the *observed* rates for the groups are compared. Statisticians consider that a difference in observed rates can be explained by one of two hypotheses: ( $H_0$ ) The actual rates are really the same, but the observed rates are different because of some combination of error-causing factors, or ( $H_1$ ) the actual rates of the groups are really different.  $H_0$  is called the **null hypothesis** (because it says there is *no* real difference);  $H_1$  is called the **alternate hypothesis**. Typically,  $H_0$  is rejected only if there is strong evidence in favor of  $H_1$ . (Thus, if the observed rates are equal, we cannot reject  $H_0$ .)

Using statistical theory, one can determine the distribution of the rate difference under the assumption that  $H_0$  is true. Then values of the rate difference that are very unlikely to occur if  $H_0$  is true are identified. More specifically, a small positive number, called **alpha** ( $\alpha$ ), is chosen; usually,  $\alpha$  is 0.05 or 0.01. (Alpha is called the **significance level** of the hypothesis test.) One can then identify limits for the difference in rates such that, if  $H_0$  is true, the probability of the difference being outside of those limits is  $\alpha$ . If the observed difference is *outside* of these limits, then the observed result is *very unlikely* to happen if  $H_0$  is true, so  $H_0$  is rejected.

Another way of looking at the same process is to calculate, assuming  $H_0$  is true, the probability that the observed difference or any greater observed difference would occur; this number is called the **P-value** of the observed result. If the P-value of a comparison is less than  $\alpha$  — that is, the observed difference is *very unlikely* to happen if the null hypothesis is true —  $H_0$  will be rejected. If the P-value of a test is greater than the significance level  $\alpha$ ,  $H_0$  will not be rejected. When a difference in rates is sufficiently large to cause the null hypothesis to be rejected for a given value of  $\alpha$ , it is called a **statistically significant** difference.

When a null hypothesis is rejected, there remains a small chance that a wrong decision has been made. If many statistical comparisons are done, even with  $\alpha = 0.01$ , the chance of making at least one wrong decision becomes a concern. In testing the differences between the total US rate and the rate for each state (or for the District of Columbia) for a given cancer, 51 statistical comparisons of the type described above are performed. Based on one of Bonferroni's inequalities (if there are  $n$  events and  $p_i$  is the probability of success in event  $i$ , then  $P(\text{at least 1 success}) < p_1 + \dots + p_n$ ) (Snedecor & Cochran, 1980; p. 115-117), the significance level  $\alpha$  for each individual comparison was set equal to  $0.01/51 \approx 0.0002$ . Thus, only individual-state-to-total-US comparisons with an associated P-value less than 0.0002 are considered to be statistically significant. That is, a *very small* significance level  $\alpha$  (0.0002) is used in order to minimize the total risk (0.01) of falsely deciding that some pair of equal rates are unequal.

*Use caution in assessing statistically significant differences.* Population size has an important role in any calculation of statistical significance. Some states may have estimated rates that are very close to the estimated total US rate, but because of their large population, the difference between their estimated rate and the estimated total US rate is found to be statistically significant. In this case, the true state rate and the true US rate are almost certainly different, because the observed difference, though small, is nearly impossible if the null hypothesis (equal rates) is true. A small difference in rates, however, may have no practical importance.

On the other hand, some smaller states may have estimated rates that differ substantially from the estimated total US rate, but because of their relatively small population, the differences are found to be statistically nonsignificant. When this happens, if the true state rate and the true US rate were equal, the probability of obtaining a difference at least as large as what has been observed is greater than  $\alpha \approx 0.0002$ . Therefore, *because the evidence against it isn't strong enough, the null hypothesis (equal rates) is not rejected*.

If the percent difference (PD) between the two rates is small, there may be some question about the importance of the difference. It is difficult to specify a minimally significant absolute PD, below which the difference would always be unimportant, because the observed PD will depend on the populations of the areas involved. It may be of value to consider the size of the PD between a state rate and the US rate in assessing the importance of a statistically significant difference. To further assist readers in interpreting

the data, the tables are footnoted to indicate variations of more than 15% between a state rate and the US rate.

Comparing individual state rates with the US rate and assessing statistical significance is not an appropriate procedure for assessing geographic clustering of state rates. Identification of states which may represent regional clusters of high or low rates would require additional statistical and graphical analyses.

For a number of cancers, the District of Columbia has the highest mortality rates. *Use caution when comparing cancer rates for the District with those from the 50 states.* The District is an entirely urban area, whereas a state includes urban, suburban, and rural areas. Mortality rates for many cancers are higher in urban areas. Also, the District has a higher percentage of blacks (about two-thirds) than any state; their higher mortality rates for several types of cancer elevate the overall rate for the District.

### INTERPRETATION OF CANCER STATISTICS

When reviewing the various cancer incidence, mortality, and survival statistics provided in this report, be aware that a number of factors may affect the interpretation of many of these statistics.

**Survival rates for all cancers combined:** The mix of cancers changes over time as the incidence of some cancers increases and the incidence of others decreases. Thus, in calculating the survival rate for all cancers combined, the proportions corresponding to the specific cancers will also change over time. Therefore, the overall cancer survival rate can fluctuate even when the survival rates for site-specific cancers remain unchanged. (While it is possible to adjust the survival rate for all cancers combined on the basis of the relative frequency of each specific cancer in some specified reference period, rates adjusted in this manner differ by only a small amount from unadjusted rates. In the future, such an adjustment may become more important if there are substantial changes in the incidence of various cancers.)

**Early detection/screening:** The improved earlier detection and diagnosis of cancers may produce an *increase* in both incidence rates and survival rates. These increases can occur as a result of the introduction of a new procedure to screen subgroups of the population for a specific cancer; they need not be related to whether use of the screening test results in a decrease in mortality from that cancer. As the proportion of cancers detected at screening increases, presumably as a result of increased screening of the population, patient survival rates will *increase*, because they are based on survival time *after diagnosis*. The interval between the time a cancer is diagnosed by a screening procedure and the time when the cancer would have been diagnosed in the absence of screening is called **lead-time** (Zelen, 1976). (Screening for breast cancer has been demonstrated to result in increased survival over and above that resulting from lead-time alone and to reduce breast cancer mortality. The benefit of screening is being studied for some other cancers.)

If a new screening procedure consistently detects cancer in a preinvasive phase, this may result in a *decrease* in survival rates for *invasive* cancer. In this case, **length-biased sampling** (Zelen, 1976) may be operating. Length-biased sampling would result in the preferential detection — in a *preinvasive* phase — of those cancers that would have had a relatively good prognosis had they progressed to invasive disease; these potentially invasive cancers would be systematically eliminated. If this occurs, the mix of cancers that are not detected at screening and progress to invasive may become less prognostically favorable, resulting in a *decrease* in survival rates for patients with invasive cancers. (Length-biased sampling may at least partially explain survival trends for cervical cancer. Other cancers possibly affected include breast, colon, rectum, and prostate.)

**Changes in diagnostic criteria:** Early detection of cancer resulting from either screening or earlier response to symptoms may result in the increasing diagnosis of small tumors that are not yet life-threatening. This may have the effect of raising the incidence and survival rates with little or no change in

mortality rates. Breast, colon, prostate, cervix uteri, bladder, and skin (melanoma) are the cancer sites most likely to be affected.

**Technological advances in diagnostic procedures:** In this report, trends in survival by stage at diagnosis are not presented for specific cancers; trends in stage distributions are presented rarely. However, it is possible to compare survival rates by stage and stage distributions given here with those for earlier time periods (as provided in previous reports or available from the SEER public-use data file). Thus, it is necessary to comment on the effect of technological advances on the diagnosis and staging of cancer.

The assignment of a given stage to a particular cancer may change over time due to advances in diagnostic technology. Introduction of new technology can give rise to a phenomenon known as **stage migration**. Stage migration occurs when diagnostic procedures change over time, resulting in an increase in the probability that a given cancer will be diagnosed in a *more advanced* stage. For example, certain distant metastases that would have been undetectable a few years ago can now be diagnosed by a computer tomography (CT) scan or by magnetic resonance imaging (MRI). Therefore, some patients who would have been diagnosed previously as having cancer in a *localized* or *regional* stage are now diagnosed as having cancer in a *distant* stage. The likely result would be to remove the worst survivors — those with previously undetected distant metastases — from the localized and regional categories and put them into the distant category. As a result, the stage-at-diagnosis distribution for a cancer may become less favorable over time, but the survival rates for each stage may improve: the early stage will *lose* cases that will survive *shorter* than those remaining in that category, while the advanced stage will *gain* cases that will survive *longer* than those already in that category. However, *overall survival would not change* (Feinstein et al., 1985). Stage migration is an important concept to understand when examining temporal trends in survival by stage at diagnosis as well as temporal trends in stage distributions; it could affect the analysis of virtually all solid tumors.

**Evolution of stage classifications:** Every few years, the American Joint Committee on Cancer produces a new cancer-staging manual (Beahrs, 1988). The evolution of such classifications reflects the identification of new prognostic factors that may influence choice of treatment. The SEER Program collects data on **extent of disease (EOD)** rather than stage; EOD is *more specific* than stage and usually determines stage, even when stage definitions change. Thus, SEER easily adapts to changes in stage definitions; moreover, trends in a newly redefined stage can usually be calculated.

For those cancers for which new prognostic variables are introduced into staging, so that previously collected EOD data cannot determine new stage categories, there can be problems in assessing trends in stage of disease. Only by reviewing the evolution of staging for a given cancer is it possible to determine what effect changes in stage definitions have had on stage-specific survival and on stage-at-diagnosis distributions. Stage migration (mentioned above) and EOD migration need also be taken into account. One reason for using the historical categories of *localized*, *regional*, and *distant* is that these categories have been fairly consistent over time.

**Interpreting relative survival rates:** The relative survival rate is the ratio of the observed survival rate to the expected survival rate for a given patient cohort. When the base population used in calculating the expected survival is similar to the cohort of cancer patients except for the latter's cancer experience, the relative survival rate approximates the cancer's cause-specific survival rate. The expected survival rate is based on mortality rates for the entire population, taking into account, as appropriate, the age, sex, race, and year of diagnosis of the patients. Assuming that the presence of cancer is the only factor that distinguishes the cancer patient cohort from the general population, the relative survival rate approximates the probability that a patient will *not* die of the diagnosed cancer within the given time interval.

A factor related to the risk of a cancer may also be related to the risk of dying from causes unrelated to the cancer. An example of such a factor is *smoking*. Smoking is a major risk factor for lung cancer; therefore, a cohort of lung cancer patients will contain a much higher proportion of smokers than does the general population. However, smoking is also a risk factor for other diseases, resulting in smokers having a shorter life expectancy than nonsmokers. Expected survival rates for lung cancer patients based on the



general population will be unduly optimistic for this reason; they will result in relative rates that are *lower* than they should be. The problem cannot be easily corrected because separate life tables for smokers and nonsmokers are not available. Amount of smoking (usually measured in pack-years) is clearly an important variable. The possibility that expected rates may not be appropriate for a given patient cohort should also be considered when examining relative survival rates for patients with cancers of the cervix uteri or breast, because the risk of these cancers has been associated with socioeconomic status (Baquet et al., 1991), which may be related to life expectancy.

Previous to the CSR for 1973-1996, the expected rate tables used were for 1970 and 1980; there were separate tables for whites, blacks, American Indians, Chinese, Japanese, Filipinos, white Hispanics, and Hawaiians. In updating the tables for 1990, several problems emerged. The US life tables are based on age, race, and sex information from death certificates. The information on race on the death certificate may not be accurate (Rosenberg et al., 1999). One reason is that funeral directors may inaccurately report race on a death certificate. Also, reported age at death, especially for those older than 85, may not be accurate because birth certificates were not issued with as much regularity in the early 1900s as they are today. Although race misclassification and age-at-death misreporting exist across all races, they may be more problematic for races other than white or black because of those races' smaller population sizes. Therefore, life tables were generated for 1970, 1980, and 1990 only for white, black, and other; these life tables were used to produce the relative survival rates in this book. There may be small variations among survival rates calculated in this CSR and those in CSRs prior to 1973-1996.

**Comparison with other databases:** The SEER data are obtained from population-based cancer registries covering about 14 percent of the US population. It is sometimes of interest to compare cancer statistics for SEER areas with those from other registries both in the US and worldwide. In making such comparisons, one must carefully consider the factors considered above for both data sources. In addition, one should assess all of the following: (1) completeness of case ascertainment, (2) rules used to determine multiple primaries, (3) follow-up, (4) rules used in assigning and coding cause of death, and (5) the sources and procedures used in obtaining population estimates. Depending on the rates being compared, there could be other confounding factors which should be considered. The same standard million population should be used for the age-adjustment of each group being compared.

It is sometimes interesting to compare survival data for cancer patients in SEER areas with data from clinical trials. *This must be done with great caution.* Survival data from clinical trials may have been obtained from a patient population that differs from that of SEER patients in prognostic factors for the given cancer; any survival comparisons would have to adjust for such differences. Also, it is necessary to verify that the methodology used in computing survival rates is the same for both data sources. Furthermore, clinical-trials patients may differ from SEER patients in characteristics that may be related to survival but are not recorded in either database. If this were true for a given cancer, it would not be possible to make valid comparisons of this type.

**Errors in data collection:** In the process of registering cancer patients, errors may be made in abstracting and coding the data, which includes demographic information, cancer site, histology, extent of disease, treatment, and patient survival. Quality control studies are periodically carried out to detect and correct this type of error, but no attempt is made to incorporate this source of error into the variance estimates of cancer rates reported here.

**Comparison of this report with previous reports:** It is important to note that most rates in this CSR were age-adjusted to the 2000 standard million US population; in some previous reports, the 1970 standard million population was used. Therefore rates in this report can not be compared to rates and trends in those reports.

The cancer registries that participate in the SEER Program submit data on all cancers diagnosed in their coverage areas to the NCI each year. Because of the dynamic nature of the registries' databases, *the reported number of new cancer cases in a particular race-sex-age-cancer category may change for a calendar year for which data have already been reported in a previous publication.* Additional cancer cases that were previously overlooked for a given diagnosis year may have been found and reported to



the central registry. There may have been follow-back of cancers diagnosed by death certificate only; successful efforts to establish the dates of diagnosis for such patients will change the number of patients reported for a given diagnosis year. Code changes may occur when a patient dies; for example, information on race is generally available on the death certificate and may be used to update a previously unknown value. There may have been elimination of duplicate records for the same patient, often due to name changes or misspellings.

Thus, a recent report may have a different number of cases for a given diagnosis year than an earlier report, with resulting effects on incidence and possibly survival rates. Population estimates may also change from one report to another for some calendar years. This occurs because the NCI receives population estimates that are regularly updated by the BOC; for example, previous population estimates for years beginning with 1990 were replaced with new estimates from the BOC. Such changes may result in some differences between incidence and mortality rates for a given calendar period as published in different reports.

### STANDARD ERRORS OF RATES

**Survival rates:** In the tables presenting survival rates, the magnitude of the standard error is given as a clue to the reliability of a given rate: the greater the standard error, the less reliable the rate. In addition, if there were fewer than 25 diagnoses in the first interval of the life table constructed to calculate survival, or if all cases became lost to follow-up within an interval, a valid survival rate could not be calculated, as is noted in the table footnotes.

The **standard error (SE)** of a relative survival rate is obtained as follows (Ederer et al., 1961):

$$SE(CR_t) = CR_t \cdot \sqrt{\frac{q_1}{e_1 - d_1} + \frac{q_2}{e_2 - d_2} + \dots + \frac{q_t}{e_t - d_t}}$$

where  $CR_t$  is the  $t$ -year relative survival rate, and for  $i = 1, \dots, t$ ,

$q_i$  is the probability of dying in year  $i$  after diagnosis,

$e_i$  is the effective number of patients at risk in year  $i$  after diagnosis, and

$d_i$  is the number of deaths in year  $i$  after diagnosis.

**Incidence and mortality rates:** The standard errors of age-adjusted incidence and mortality rates are often not specified. However, the reader can approximate the SE of a particular incidence or mortality rate by the following formula for the SE of a crude incidence or mortality rate (Keyfitz, 1966):

$$SE(\text{rate}) \approx \text{rate} / \sqrt{\text{cancer cases or deaths}}$$

Appendix Tables A-1 and A-2 provide numbers of cancer diagnoses within SEER areas and numbers of deaths in the entire US, respectively, by race and sex for the most recent 5-year period. These can be used to obtain approximations of the standard errors for associated age-adjusted rates for the same time period using the above formula. To approximate the standard error of a rate for a single year, use the formula but substitute the cancer cases or deaths with the number of cancer cases or deaths divided by 5.

### REFERENCES

Baquet CR, Horm JW, Gibbs T, Greenwald P. Socioeconomic factors and cancer incidence among blacks and whites. *J Natl Cancer Inst* 1991; 83:551-557.

Beahrs OH, Henson DE, Hutter RV, Myers MH, editors. *Manual for Staging of Cancer*, 3rd ed. Philadelphia (PA): Lippincott; 1988.

Breslow L (Chairman, Extramural Committee to Assess Measures of Progress Against Cancer). *Measurement of progress against cancer: Final report to the Senate Appropriations Committee*. Bethesda: National Cancer Institute; 1988.

Brookmeyer R, & Damiano A. Statistical methods for short-term projections of AIDS incidence. *Statistics in Medicine* 1989;8:23-34.

Byrne J, Kessler LG, Devesa SS. The prevalence of cancer among adults in the United States: 1987. *Cancer* 1992;68:2154-9.

Capocaccia R, De Angelis R. Estimating the completeness of prevalence based on cancer registry data. *Statistics in Medicine* 1997;16:425-40.

Clegg LX, Feuer EJ, Midthune D, Fay MP, Hankey BF. Impact of reporting delay and reporting error on cancer incidence rates and trends. *J Natl Cancer Inst* 2002;94:1537-1545.

Clegg LX, Mitchell GH, Feuer EJ. Estimating the variance of disease prevalence estimates from population-based registries. Technical report 2001. For a copy contact [prevalence@ims.nci.nih.gov](mailto:prevalence@ims.nci.nih.gov).

Ederer F, Axtell LM, Cutler SJ. The relative survival rate: A statistical methodology. *J Natl Cancer Inst Monogr* 1961;6:101-121.

Elandt-Johnson RC, Johnson NL. *Survival Models and Data Analysis*. New York (NY): Wiley; 1980.

Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon: Stage migration and new diagnostic techniques as a source of misleading statistics for survival of cancer. *New Engl J Med* 1985;312:1604-1608.

Feldman AR, Kessler L, Myers M, Naughton MD. The prevalence of cancer: Estimates based on the Connecticut Tumor Registry. *New Engl J Med* 1986; 315:1394-1397.

Feuer EJ, Wun L-M, Boring CC. Probability of developing cancer. In: Miller BA, Ries LAG, Hankey BF, Kosary CL, Edwards BK, editors. *Cancer Statistics Review: 1973-1989*, National Cancer Institute, NIH Pub. No. 92-2789, 1992. p. XXX.1-8.

Feuer EJ, Wun L-M, Boring CC, Flanders WD, Timmel MJ, Tong T. The lifetime risk of developing breast cancer. *J Natl Cancer Inst* 1993;85:892-897.

Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S, editors. *International Classification of Diseases for Oncology*, 3rd ed. Geneva: World Health Organization; 2000.

Gail MH, Kessler L, Midthune D, Scoppa S. Two approaches for estimating disease prevalence from population-based registries of incidence and total mortality. *Biometrics* 1999;55:1137-44.

Hahn RA, Mulinare J, Teutsch SM. Inconsistencies in coding of race and ethnicity between birth and death in U.S. infants. *JAMA* 1992;267:259-263.

Harris JE. Reporting delays and the incidence of AIDS. *Journal of the American Statistical Association* 1990;85:915-924.

Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun M. Cancer statistics, 2003. *CA Cancer J Clin* 2003;53:5-26.

Keyfitz N. Sampling variance of standardized mortality rates. *Hum Biol* 1966;38:309-317.

Kim H-J, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. *Stat Med* 2000;19:335-351.

Kleinbaum DG, Kupper LL, Muller KE. *Applied Regression Analysis and Other Multivariable Methods*, 2nd ed. Boston (MA): PWS-Kent, 1988. p. 266-268.

Mariotto A, Gigli A, Capocaccia R, Clegg L, Scoppa S, Ries LA, Tesauro GS, Rowland JS, Feuer EJ. Complete and limited duration prevalence estimates. *SEER Cancer Statistics Review, 1973-1999* 2002;19.

Merrill RM, Feuer EJ, Capocaccia R, Mariotto A. Cancer prevalence estimates based on tumor registry data in the SEER Program. *Int J Epidemiol* 2000;29:197-207.

Pagano M, Tu XM, De Gruttola V, & MaWhinney S. Regression analysis of censored and truncated data: estimating reporting-delay distributions and AIDS incidence from surveillance data. *Biometrics* 1994;50:1203-1214.

Percy C, Ries LAG, Van Holten VD. The accuracy of liver cancer as the underlying cause of death on death certificates. *Public Health Rep* 1990;105:361-368.

Percy C, Van Holten V, Muir C, editors. *International Classification of Diseases for Oncology*, 2nd ed. Geneva: World Health Organization;1990.

Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg LX, Edwards BK (eds). *SEER Cancer Statistics Review, 1973-1997*, National Cancer Institute. NIH Pub. No. 00-2789. Bethesda, MD, 2000.

Rosenberg HM, Maurer JD, Sorlie PD, Johnson NJ, MacDorman MF, Hoyert DL, Spitler JF, Scott C. Quality of death rates by race and Hispanic origin: A summary of current research. Hyattsville (MD): National Center for Health Statistics; Vital and Health Statistics, Series 2, No. 128, 1999.

Snedecor GW, Cochran WG. *Statistical Methods*, 7th ed. Ames (IA): Iowa State University Press; 1980.

US Bureau of the Census. *Current Population Reports; Series P-25 No. 985*. Washington (DC): US Government Printing Office; 1986.

Zelen M. Theory of early detection of breast cancer in the general population. In: Heuson J-C, Matthei WH, Rozencweig M, editors. *Breast Cancer: Trends in Research and Treatment*. New York (NY): Raven Press; 1976. p. 287-299.

Table I-1

## ESTIMATED NEW CANCER CASES AND DEATHS FOR 2003

## All Races, By Sex

Primary Site	Estimated New Cases			Estimated Deaths		
	Total	Males	Females	Total	Males	Females
All Sites	1,334,100	675,300	658,800	556,500	285,900	270,600
Oral Cavity and Pharynx	27,700	18,200	9,500	7,200	4,800	2,400
Tongue	7,100	4,700	2,400	1,700	1,100	600
Mouth	9,200	4,800	4,400	1,900	1,100	800
Pharynx	8,300	6,300	2,000	2,000	1,400	600
Other Oral Cavity	3,100	2,400	700	1,600	1,200	400
Digestive System	252,400	132,300	120,100	133,600	71,900	61,700
Esophagus	13,900	10,600	3,300	13,000	9,900	3,100
Stomach	22,400	13,400	9,000	12,100	7,000	5,100
Small Intestine	5,300	2,700	2,600	1,100	600	500
Colon	105,500	49,000	56,500			
Rectum <sup>a</sup>	42,000	23,800	18,200	57,100	28,300	28,800
Anus, Anal Canal, and Anorectum	4,000	1,700	2,300	500	200	300
Liver and Intrahepatic Bile Duct	17,300	11,700	5,600	14,400	9,200	5,200
Gallbladder and Other Biliary	6,800	3,100	3,700	3,500	1,300	2,200
Pancreas	30,700	14,900	15,800	30,000	14,700	15,300
Other Digestive	4,500	1,400	3,100	1,900	700	1,200
Respiratory System	185,800	102,200	83,600	163,700	93,400	70,300
Larynx	9,500	7,100	2,400	3,800	3,000	800
Lung and Bronchus	171,900	91,800	80,100	157,200	88,400	68,800
Other Respiratory	4,400	3,300	1,100	2,700	2,000	700
Bones and Joints	2,400	1,300	1,100	1,300	700	600
Soft Tissue	8,300	4,500	3,800	3,900	2,000	1,900
Skin (excl. basal & squamous)	58,800	32,300	26,500	9,800	6,200	3,600
Melanoma of the Skin <sup>b</sup>	54,200	29,900	24,300	7,600	4,700	2,900
Other non-epithelial skin	4,600	2,400	2,200	2,200	1,500	700
Breast <sup>b</sup>	212,600	1,300	211,300	40,200	400	39,800
Genital Organs	313,600	229,900	83,700	56,300	29,500	26,800
Cervix (uterus)	12,200		12,200	4,100		4,100
Endometrium (uterus)	40,100		40,100	6,800		6,800
Ovary	25,400		25,400	14,300		14,300
Vulva	4,000		4,000	800		800
Vagina and other genital organs, female	2,000		2,000	800		800
Prostate	220,900	220,900		28,900	28,900	
Testis	7,600	7,600		400	400	
Penis and other genital organs, male	1,400	1,400		200	200	
Urinary System	91,700	63,300	28,400	25,100	16,400	8,700
Urinary Bladder	57,400	42,200	15,200	12,500	8,600	3,900
Kidney and Renal Pelvis	31,900	19,500	12,400	11,900	7,400	4,500
Ureter and other urinary organs	2,400	1,600	800	700	400	300
Eye and Orbit	2,200	1,100	1,100	200	100	100
Brain and Other Nervous System	18,300	10,200	8,100	13,100	7,300	5,800
Endocrine System	23,800	6,600	17,200	2,300	1,100	1,200
Thyroid	22,000	5,700	16,300	1,400	600	800
Other Endocrine	1,800	900	900	900	500	400
Lymphoma	61,000	32,300	28,700	24,700	12,900	11,800
Hodgkin Lymphoma	7,600	4,000	3,600	1,300	700	600
Non-Hodgkin Lymphoma	53,400	28,300	25,100	23,400	12,200	11,200
Myeloma	14,600	7,800	6,800	10,900	5,400	5,500
Leukemia	30,600	17,900	12,700	21,900	12,100	9,800
Lymphocytic Leukemias	10,900	6,700	4,200	5,800	3,300	2,500
Myeloid Leukemias	14,800	8,300	6,500	9,500	5,200	4,300
Other leukemia	4,900	2,900	2,000	6,600	3,600	3,000
All Other Sites <sup>c</sup>	30,300	14,100	16,200	42,300	21,700	20,600

Cancer Facts &amp; Figures - 2003, American Cancer Society (ACS), Atlanta, Georgia, 2003.

Excludes basal and squamous cell skin and *in situ* carcinomas except urinary bladder.

Incidence projections are based on rates from the NCI SEER Program 1979-1999.

<sup>a</sup> Estimated deaths for colon & rectum cancers are combined.<sup>b</sup> Carcinoma *in situ* of the breast accounts for about 55,700 new cases annually, and melanoma *in situ* accounts for about 37,700 new cases annually.<sup>c</sup> More deaths than cases suggests lack of specificity in recording underlying causes of death on death certificate.

Table I-2

51-YEAR TRENDS IN U.S. CANCER DEATH RATES<sup>a</sup>

All Races, Males and Females

All Primary Cancer Sites Combined

Age Group	1950	1975	2000	Annual Percent Change		Total Percent Change
				1950-1975	1975-2000	1950-2000
0-4	11.1	5.2	2.7	-2.8	-2.9	-76.0
5-14	6.7	4.8	2.5	-1.0	-2.8	-62.9
15-24	8.6	6.6	4.4	-0.7	-1.7	-49.1
25-34	20.4	15.1	9.9	-1.2	-1.4	-51.7
35-44	63.6	53.3	36.7	-0.4	-1.4	-42.3
45-54	174.2	178.0	127.4	0.2	-1.4	-26.9
55-64	391.3	420.2	366.6	0.3	-0.5	-6.3
65-74	710.0	778.7	816.2	0.4	0.2	15.0
75-84	1,167.2	1,160.9	1,335.0	0.0	0.5	14.4
85+	1,450.7	1,437.9	1,819.4	-0.2	0.8	25.4
All Ages	195.4	199.1	199.6	0.1	0.0	2.2

Lung and Bronchus Cancer<sup>b</sup>

Age Group	1950	1975	2000	Annual Percent Change		Total Percent Change
				1950-1975	1975-2000	1950-2000
0-4	-	-	-	-	-	-
5-14	-	-	-	-	-	-
15-24	0.2	0.1	-	-2.5	-0.9	-63.9
25-34	0.8	0.9	0.5	0.4	-1.6	-38.4
35-44	4.6	10.6	6.2	3.7	-2.5	34.4
45-54	20.2	48.8	31.6	3.6	-2.0	56.2
55-64	48.9	122.6	122.6	3.6	0.0	150.9
65-74	59.4	196.2	284.6	4.5	1.5	378.8
75-84	55.4	192.3	371.6	5.3	2.5	571.0
85+	42.3	135.5	302.7	5.1	3.1	615.8
All Ages	14.9	42.8	56.2	4.2	1.0	276.0

Source: NCHS public use data file.

-     Statistic not shown. Rate based on less than 25 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

<sup>a</sup>     Rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population by 5-year age groups.

<sup>b</sup>     Due to coding changes throughout the years, Lung and Bronchus includes trachea and pleura.

Table I-3

## SUMMARY OF CHANGES IN CANCER INCIDENCE AND MORTALITY, 1950-2000 AND

## 5-YEAR RELATIVE SURVIVAL RATES, 1950-1999

Males and Females, By Primary Cancer Site

Primary Site	All Races		Whites					
	Estimated Cancer Cases in 2000 <sup>a</sup>	Actual Cancer Deaths in 2000 <sup>b</sup>	Percent Change 1950-2000 <sup>c</sup>				5-Year Relative Survival Rates (Percent) <sup>e</sup>	
			Incidence <sup>d</sup>		U.S. Mortality <sup>b</sup>			
			Total	APC	Total	APC	1950-54	1992-99
Oral cavity and Pharynx	30,200	7,492	-31.2	-0.5	-49.7	-1.2	46	59.7
Esophagus	12,300	12,232	16.0	0.7	26.9	0.6	4	15.4
Stomach	21,500	12,645	-74.3	-2.2	-83.3	-3.5	12	21.4
Colon and Rectum	130,200	57,477	20.4	0.2	-38.8	-1.0	37	63.0
Colon	93,800	48,570	40.7	0.4	-25.6	-0.5	41	63.0
Rectum	36,400	8,907	-12.8	-0.4	-68.6	-2.7	40	63.0
Liver and Intrahep	15,300	16,582	294.9	2.5	27.3	0.6	1	6.8
Pancreas	28,300	29,331	36.5	0.3	21.3	0.1	1	4.4
Larynx	10,100	3,861	43.0	0.2	-23.3	-0.5	52	66.6
Lung and Bronchus	164,100	155,788	294.3	2.3	270.0	2.3	6	15.1
Males	89,500	90,676	206.7	1.4	203.9	1.7	5	13.4
Females	74,600	65,112	697.4	4.4	611.5	4.4	9	17.2
Melanoma of the skin	47,700	7,420	619.1	4.3	165.1	1.8	49	89.8
Breast(females)	182,800	41,872	90.6	1.5	-19.5	-0.2	60	87.9
Cervix uteri	12,800	4,200	-77.6	-2.4	-79.1	-3.5	59	72.9
Corpus and Uterus, NOS	36,100	6,585	18.5	-0.2	-68.6	-2.1	72	86.3
Ovary	23,100	14,453	15.7	0.4	3.6	-0.2	30	52.4
Prostate	180,400	31,078	282.9	3.3	-4.0	0.3	43	98.4
Testis	6,900	338	167.6	2.1	-72.6	-3.0	57	95.8
Urinary bladder	53,200	12,306	96.9	1.2	-31.0	-0.9	53	82.6
Kidney and Renal pelvis	31,200	12,038	196.1	2.2	42.4	0.7	34	62.9
Brain and Other nervous	16,500	12,655	159.7	1.3	58.0	0.8	21	32.1
Thyroid	18,400	1,328	240.8	2.1	-44.8	-1.6	80	96.1
Hodgkin lymphoma	7,400	1,287	21.0	0.2	-75.2	-3.3	30	85.0
Non-Hodgkin lymphoma	54,900	22,553	252.0	3.0	152.5	1.8	33	57.2
Myeloma	13,600	10,697	291.6	1.9	254.4	1.9	6	30.9
Leukemia	30,800	21,339	31.5	0.4	9.6	-0.2	10	47.6
Childhood(0-14 yrs)	8,600	1,526	62.4	0.8	-69.0	-2.8	20	78.7
All Sites	1,220,100	553,080	88.7	1.5	0.4	0.1	35	64.4

The APC is the Annual Percent Change over the time interval. Rates used in the calculation of the APC are age-adjusted to the 1970 U.S. standard population.

<sup>a</sup> Facts and Figures, 1999. American Cancer Society, Atlanta, Georgia, 1999.  
<sup>b</sup> NCHS public use tape. Due to coding changes throughout the years: Colon excludes other digestive tract; Rectum includes anal canal; Liver & Intrahep includes gallbladder & biliary tract; NOS; Lung & Bronchus includes trachea & pleura; Ovary includes fallopian tube; Urinary bladder includes other urinary organs; Kidney & Renal pelvis includes ureter; NHL and myeloma each include a small number of leukemias; NHL includes a small number of ill-defined sites.

<sup>c</sup> All Sites, Liver & Intrahep, Brain & Other nervous and Childhood cancers are for all races as opposed to whites.

<sup>d</sup> Data prior to 1973 are from Devesa, Silverman, Young, et al. Cancer Incidence and Mortality Trends Among Whites in the United States, 1947-84. JNCI 1987; 79:701-770 with the exception of All Sites, Liver & Intrahep, Brain & Other nervous and Childhood cancers which come from historical Connecticut data. Data for 1973-2000 are from the same areas used in Devesa or the Connecticut registry of the SEER Program.

<sup>e</sup> Rates for 1950-54 are from NCI Survival Report 5 with the exception of All Sites, Oral cavity & Pharynx, Colon & Rectum, Non-Hodgkin lymphomas and Childhood cancers which come from historical Connecticut data. Rates for 1992-99 are from the SEER Program with the exception of the sites just listed which come from the Connecticut registry of the SEER Program.

Table I-4  
AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES  
By Primary Cancer Site, Sex and Time Period

All Races									
Site	Incidence <sup>a</sup> (1996-2000)			US Mortality <sup>b</sup> (1996-2000)			Survival <sup>c</sup> (1992-1999)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Sites	472.3	555.8	417.9	202.3	255.5	168.3	63.0	62.6	63.5
Oral Cavity & Pharynx:	10.9	16.3	6.5	2.9	4.4	1.7	57.2	55.7	60.4
Lip	1.0	1.9	0.4	0.0	0.1	0.0	94.4	95.4	89.7
Tongue	2.5	3.7	1.6	0.7	1.0	0.4	53.1	51.1	56.9
Salivary gland	1.2	1.6	1.0	0.2	0.4	0.2	74.7	70.0	80.3
Floor of mouth	0.9	1.2	0.5	0.1	0.1	0.0	51.7	50.8	53.9
Gum & other oral cavity	1.7	2.1	1.4	0.5	0.6	0.4	54.8	48.3	64.1
Nasopharynx	0.8	1.1	0.4	0.2	0.4	0.1	57.2	58.1	55.4
Tonsil	1.3	2.1	0.5	0.2	0.3	0.1	54.0	54.0	54.1
Oropharynx	0.3	0.5	0.2	0.2	0.3	0.1	37.3	37.4	37.4
Hypopharynx	0.9	1.5	0.4	0.1	0.3	0.1	30.9	30.4	32.5
Other oral cavity & pharynx	0.3	0.5	0.2	0.6	1.0	0.3	32.3	34.7	26.0
Digestive System:	92.0	113.5	75.6	47.9	61.6	37.8	43.8	41.9	45.9
Esophagus	4.5	7.7	2.1	4.3	7.6	1.8	14.0	13.9	14.5
Stomach	9.1	13.0	6.2	4.8	6.9	3.4	22.5	21.3	24.6
Small intestine	1.7	1.9	1.4	0.4	0.5	0.3	52.6	51.3	53.9
Colon & Rectum:	54.2	64.2	46.7	21.2	25.8	18.0	62.3	62.4	62.3
Colon	39.1	44.9	34.9	18.2	21.9	15.6	62.3	62.7	61.9
Rectum	15.0	19.3	11.8	3.0	4.0	2.4	62.4	61.7	63.3
Anus, anal canal & anorectum	1.3	1.2	1.4	0.2	0.1	0.2	64.4	56.8	70.0
Liver & Intrahep:	5.9	9.0	3.4	4.5	6.6	2.9	6.9	6.7	7.4
Liver	5.0	7.9	2.7	3.6	5.5	2.1	7.5	7.0	8.8
Intrahep bile duct	0.9	1.1	0.7	0.9	1.1	0.8	3.9	4.7	3.0
Gallbladder	1.2	0.8	1.5	0.8	0.5	0.9	15.1	14.5	15.2
Other biliary	1.5	1.8	1.2	0.6	0.7	0.5	18.9	20.1	17.8
Pancreas	11.1	12.6	9.8	10.5	12.2	9.2	4.4	4.3	4.5
Retroperitoneum	0.4	0.5	0.4	0.1	0.1	0.1	48.2	46.1	50.1
Peritoneum, omentum & mesentery	0.6	0.2	1.0	0.2	0.1	0.3	31.0	17.9	34.4
Other digestive system	0.4	0.5	0.4	0.3	0.3	0.2	7.7	4.8	10.8
Respiratory System:	68.4	90.7	52.2	58.6	82.8	41.5	18.4	18.2	18.7
Nose, nasal cavity & middle ear	0.7	0.9	0.6	0.2	0.2	0.1	55.9	55.9	55.8
Larynx	3.9	7.0	1.5	1.4	2.6	0.5	64.7	66.4	58.8
Lung & bronchus	62.6	80.8	49.6	56.8	79.5	40.7	14.9	13.2	17.0
Pleura	0.9	1.8	0.3	0.1	0.3	0.1	7.1	5.2	13.9
Trachea & other respiratory organs	0.2	0.3	0.1	0.1	0.1	0.1	44.2	45.3	41.6
Bones & joints	0.9	1.0	0.7	0.4	0.6	0.4	69.6	67.9	71.9
Soft tissue (incl heart)	2.9	3.4	2.5	1.4	1.6	1.3	67.6	67.4	67.9
Skin (ex basal & squam):	19.4	25.4	15.0	3.5	5.3	2.2	80.2	72.7	91.3
Melanoma of the skin	16.6	21.0	13.5	2.7	3.9	1.8	89.6	87.7	91.9
Other non-epithelial skin	2.9	4.4	1.6	0.8	1.4	0.4	45.5	36.8	86.3
Breast	73.9	1.2	135.0	15.8	0.3	27.7	86.6	81.6	86.6
Breast (in situ)	15.4	0.2	28.7	-	-	-	100.0	96.8	100.0

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population by 5-year age groups. Survival rates are expressed as percents.

- <sup>a</sup> SEER 12 areas.
- <sup>b</sup> NCHS public use data file.
- <sup>c</sup> SEER 9 areas.
- Statistic could not be calculated.

Table I-4 - continued  
AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES  
By Primary Cancer Site, Sex and Time Period

All Races									
Site	Total	Incidence <sup>a</sup> (1996-2000)		Total	US Mortality <sup>b</sup> (1996-2000)		Total	Survival <sup>c</sup> (1992-1999)	
		Males	Females		Males	Females		Males	Females
Female Genital System:	29.6	-	54.5	9.6	-	16.8	71.4	-	71.4
Cervix uteri	5.0	-	9.6	1.6	-	3.0	71.3	-	71.3
Corpus uteri	13.2	-	24.1	1.2	-	2.0	85.3	-	85.3
Uterus, NOS	0.2	-	0.4	1.2	-	2.1	29.4	-	29.4
Ovary	9.1	-	16.8	5.0	-	8.8	53.0	-	53.0
Vagina	0.4	-	0.7	0.2	-	0.3	46.1	-	46.1
Vulva	1.3	-	2.2	0.3	-	0.4	76.3	-	76.3
Other female genital system	0.4	-	0.7	0.1	-	0.2	64.9	-	64.9
Male Genital System:	76.7	176.4	-	12.3	33.4	-	97.2	97.2	-
Prostate	73.7	170.1	-	12.1	32.9	-	97.5	97.5	-
Testis	2.6	5.2	-	0.1	0.3	-	95.5	95.5	-
Penis	0.3	0.8	-	0.1	0.2	-	74.9	74.9	-
Other male genital system	0.2	0.4	-	0.0	0.0	-	78.5	78.5	-
Urinary System:	32.3	52.8	17.3	8.8	14.1	5.3	74.4	76.8	69.3
Urinary bladder	20.3	36.0	9.1	4.4	7.7	2.3	81.8	84.0	75.7
Kidney & renal pelvis	11.1	15.4	7.7	4.2	6.1	2.8	62.6	62.5	62.6
Ureter	0.5	0.8	0.3	0.1	0.2	0.1	55.6	54.9	56.8
Other urinary system	0.3	0.5	0.2	0.1	0.1	0.1	63.7	69.8	52.9
Eye & Orbit	0.8	0.9	0.6	0.1	0.1	0.1	82.0	82.4	81.6
Brain & Nervous System: <sup>d</sup>	6.4	7.7	5.3	4.7	5.7	3.8	32.8	33.1	32.5
Brain	6.0	7.2	5.0	-	-	-	30.2	30.5	29.8
Cranial nerves & other nervous system	0.4	0.4	0.4	-	-	-	73.6	76.0	71.1
Endocrine System:	7.5	4.3	10.5	0.8	0.8	0.8	92.6	87.0	94.7
Thyroid	6.8	3.6	9.9	0.5	0.4	0.5	95.8	92.4	96.9
Other endocrine & thymus	0.6	0.7	0.6	0.3	0.4	0.3	60.2	62.3	57.8
Lymphoma:	21.8	26.5	18.0	9.1	11.3	7.4	60.7	57.5	64.5
Hodgkin lymphoma	2.7	3.0	2.4	0.5	0.6	0.4	84.1	82.4	86.0
Non-Hodgkin lymphoma	19.1	23.5	15.6	8.6	10.7	7.0	56.1	52.9	60.1
Myeloma	5.6	7.0	4.6	3.9	4.8	3.2	31.5	33.5	29.4
Leukemia:	12.1	15.8	9.3	7.7	10.3	5.9	46.3	47.1	45.3
Lymphocytic:	5.5	7.3	4.0	2.3	3.2	1.6	70.6	70.3	71.1
Acute lymphocytic	1.5	1.7	1.3	0.5	0.6	0.4	63.5	61.6	66.1
Chronic lymphocytic	3.5	4.9	2.5	1.6	2.4	1.1	73.5	72.9	74.5
Other lymphocytic	0.5	0.7	0.3	0.2	0.2	0.1	80.0	83.5	70.6
Myeloid & Monocytic:	5.8	7.4	4.6	3.5	4.5	2.8	23.8	23.4	24.2
Acute myeloid	3.7	4.6	3.1	2.5	3.2	2.0	18.7	17.5	20.0
Chronic myeloid	1.7	2.2	1.2	0.8	1.0	0.6	34.9	35.0	34.9
Acute monocytic	0.2	0.3	0.2	0.1	0.1	0.0	19.2	21.5	15.7
Other myeloid & monocytic	0.2	0.2	0.1	0.2	0.2	0.1	23.1	23.8	22.3
Other:	0.8	1.0	0.7	2.0	2.6	1.5	15.1	15.9	14.2
Other acute	0.4	0.6	0.4	1.0	1.3	0.8	10.1	10.4	9.3
Aleukemic, subleuk & NOS	0.4	0.5	0.3	1.0	1.3	0.8	22.4	23.5	21.3
Ill-defined & unspecified	11.4	13.0	10.2	14.8	18.4	12.3	13.8	15.8	12.0

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population by 5-year age groups. Survival rates are expressed as percents.

<sup>a</sup> SEER 12 areas.

<sup>b</sup> NCHS public use data file.

<sup>c</sup> SEER 9 areas.

<sup>d</sup> Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

- Statistic could not be calculated.



Table I-5  
AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES  
By Primary Cancer Site, Sex and Time Period

Whites									
Site	Incidence <sup>a</sup> (1996-2000)			US Mortality <sup>b</sup> (1996-2000)			Survival <sup>c</sup> (1992-1999)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Sites	479.8	555.9	431.8	199.1	249.5	166.9	64.4	64.2	64.7
Oral Cavity & Pharynx:	10.8	16.0	6.5	2.7	4.0	1.6	59.7	58.9	61.2
Lip	1.2	2.2	0.4	0.0	0.1	0.0	94.6	95.5	90.1
Tongue	2.6	3.8	1.6	0.6	0.9	0.4	54.7	53.4	57.3
Salivary gland	1.3	1.7	1.0	0.3	0.4	0.2	74.2	69.6	79.8
Floor of mouth	0.9	1.2	0.6	0.1	0.1	0.0	54.3	54.0	54.7
Gum & other oral cavity	1.7	2.1	1.5	0.5	0.6	0.4	57.4	52.2	64.3
Nasopharynx	0.4	0.6	0.2	0.2	0.3	0.1	51.9	52.4	50.9
Tonsil	1.3	2.1	0.5	0.2	0.3	0.1	57.3	57.8	55.8
Oropharynx	0.3	0.5	0.2	0.2	0.3	0.1	40.4	40.9	39.6
Hypopharynx	0.8	1.4	0.4	0.1	0.2	0.1	33.1	32.6	34.5
Other oral cavity & pharynx	0.3	0.5	0.2	0.5	0.9	0.3	35.2	37.8	28.6
Digestive System:	88.7	109.3	73.0	45.9	59.0	36.1	45.4	43.6	47.3
Esophagus	4.4	7.5	2.0	4.1	7.3	1.7	15.4	15.2	16.2
Stomach	7.7	11.2	5.1	4.2	6.1	2.9	21.4	20.0	23.8
Small intestine	1.6	1.9	1.4	0.4	0.5	0.3	54.3	52.6	56.0
Colon & Rectum:	53.9	64.1	46.2	20.7	25.3	17.5	63.0	63.1	63.0
Colon	38.9	44.9	34.5	17.7	21.4	15.1	63.0	63.4	62.7
Rectum	15.0	19.2	11.8	3.0	3.9	2.3	63.0	62.4	63.8
Anus, anal canal & anorectum	1.4	1.3	1.5	0.2	0.1	0.2	66.6	60.6	70.7
Liver & Intrahep:	4.8	7.3	2.8	4.2	6.0	2.7	6.8	6.1	8.1
Liver	3.9	6.1	2.1	3.2	4.9	1.9	7.5	6.4	10.0
Intrahep bile duct	0.9	1.1	0.7	0.9	1.1	0.8	4.2	5.1	2.9
Gallbladder	1.2	0.8	1.5	0.7	0.5	0.9	14.5	13.3	14.9
Other biliary	1.4	1.8	1.2	0.6	0.7	0.5	19.5	21.9	17.2
Pancreas	10.8	12.4	9.5	10.3	12.0	8.9	4.4	4.3	4.5
Retroperitoneum	0.4	0.5	0.4	0.1	0.1	0.1	49.9	47.9	51.6
Peritoneum, omentum & mesentery	0.7	0.2	1.1	0.2	0.1	0.3	30.1	13.7	34.4
Other digestive system	0.4	0.5	0.4	0.2	0.3	0.2	6.7	2.5	11.5
Respiratory System:	69.1	89.4	54.5	58.4	81.1	42.2	18.8	18.6	19.0
Nose, nasal cavity & middle ear	0.7	0.9	0.6	0.2	0.2	0.1	58.8	59.7	57.6
Larynx	3.9	6.9	1.5	1.3	2.4	0.5	66.6	68.3	60.3
Lung & bronchus	63.2	79.4	51.9	56.7	78.1	41.5	15.1	13.4	17.2
Pleura	1.0	2.0	0.3	0.1	0.3	0.1	7.1	5.3	14.1
Trachea & other respiratory organs	0.2	0.3	0.2	0.1	0.1	0.1	43.2	44.9	39.4
Bones & joints	0.9	1.0	0.8	0.5	0.6	0.4	69.9	68.4	72.1
Soft tissue (incl heart)	2.9	3.4	2.5	1.4	1.6	1.3	68.8	69.0	68.5
Skin (ex basal & squam):	22.5	28.9	17.7	3.9	5.8	2.5	81.7	74.7	91.7
Melanoma of the skin	19.6	24.6	16.1	3.1	4.4	2.0	89.8	87.8	92.1
Other non-epithelial skin	2.9	4.4	1.6	0.8	1.4	0.4	46.3	37.5	86.9
Breast	76.5	1.2	140.8	15.4	0.3	27.2	87.9	85.0	87.9
Breast (in situ)	15.7	0.2	29.6	-	-	-	100.0	95.4	100.0

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population by 5-year age groups. Survival rates are expressed as percents.

<sup>a</sup> SEER 12 areas.  
<sup>b</sup> NCHS public use data file.  
<sup>c</sup> SEER 9 areas.  
 - Statistic could not be calculated.

Table I-5 - continued  
AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES  
By Primary Cancer Site, Sex and Time Period

Whites									
Site	Total	Incidence <sup>a</sup> (1996-2000)		Total	US Mortality <sup>b</sup> (1996-2000)		Total	Survival <sup>c</sup> (1992-1999)	
		Males	Females		Males	Females		Males	Females
Female Genital System:	30.7	-	57.0	9.4	-	16.6	72.4	-	72.4
Cervix uteri	4.7	-	9.2	1.4	-	2.7	72.9	-	72.9
Corpus uteri	14.0	-	25.7	1.1	-	1.9	87.0	-	87.0
Uterus, NOS	0.2	-	0.4	1.1	-	1.9	29.1	-	29.1
Ovary	9.6	-	17.9	5.2	-	9.1	52.4	-	52.4
Vagina	0.4	-	0.7	0.1	-	0.2	45.9	-	45.9
Vulva	1.4	-	2.4	0.3	-	0.5	76.3	-	76.3
Other female genital system	0.4	-	0.7	0.1	-	0.2	65.5	-	65.5
Male Genital System:	75.2	171.5	-	11.3	30.7	-	98.1	98.1	-
Prostate	71.7	164.3	-	11.1	30.2	-	98.4	98.4	-
Testis	3.1	6.1	-	0.1	0.3	-	95.8	95.8	-
Penis	0.3	0.8	-	0.1	0.2	-	76.0	76.0	-
Other male genital system	0.1	0.3	-	0.0	0.0	-	78.6	78.6	-
Urinary System:	34.6	56.9	18.2	9.0	14.5	5.3	75.5	77.9	70.2
Urinary bladder	22.3	39.6	9.8	4.5	8.0	2.3	82.6	84.6	77.0
Kidney & renal pelvis	11.4	15.9	7.9	4.3	6.2	2.8	62.9	63.1	62.5
Ureter	0.6	0.8	0.4	0.1	0.2	0.1	57.9	58.5	56.9
Other urinary system	0.3	0.5	0.2	0.1	0.1	0.1	63.6	67.4	55.7
Eye & Orbit	0.9	1.0	0.7	0.1	0.1	0.1	81.4	82.0	80.8
Brain & Nervous System: <sup>d</sup>	7.1	8.5	5.9	5.0	6.0	4.1	32.1	32.3	31.8
Brain	6.7	8.0	5.6	-	-	-	29.3	29.5	29.2
Cranial nerves & other nervous system	0.4	0.4	0.4	-	-	-	75.9	79.2	72.0
Endocrine System:	7.7	4.5	10.9	0.8	0.8	0.7	93.0	87.9	95.0
Thyroid	7.1	3.8	10.3	0.5	0.4	0.5	96.1	92.7	97.2
Other endocrine & thymus	0.6	0.7	0.5	0.3	0.4	0.3	59.1	62.3	55.2
Lymphoma:	23.0	27.8	19.0	9.4	11.7	7.8	61.7	58.8	65.2
Hodgkin lymphoma	3.0	3.3	2.6	0.5	0.6	0.4	85.0	83.5	86.7
Non-Hodgkin lymphoma	20.1	24.5	16.4	8.9	11.1	7.3	57.2	54.1	60.9
Myeloma	5.2	6.7	4.1	3.5	4.5	2.9	30.9	33.1	28.5
Leukemia:	12.7	16.6	9.9	7.9	10.6	6.0	47.6	48.3	46.6
Lymphocytic:	6.0	7.9	4.5	2.3	3.3	1.7	71.8	71.6	72.2
Acute lymphocytic	1.6	1.8	1.5	0.5	0.7	0.4	63.4	61.4	66.2
Chronic lymphocytic	3.8	5.3	2.7	1.6	2.4	1.1	74.7	74.1	75.5
Other lymphocytic	0.5	0.8	0.3	0.2	0.2	0.1	82.8	86.4	72.8
Myeloid & Monocytic:	5.9	7.6	4.7	3.6	4.6	2.8	23.6	23.1	24.2
Acute myeloid	3.8	4.8	3.1	2.6	3.3	2.1	18.2	16.8	19.8
Chronic myeloid	1.7	2.3	1.3	0.8	1.0	0.6	34.9	35.0	34.8
Acute monocytic	0.3	0.3	0.2	0.1	0.1	0.0	21.3	23.0	17.9
Other myeloid & monocytic	0.2	0.2	0.1	0.2	0.2	0.1	23.9	26.6	20.9
Other:	0.8	1.1	0.7	2.0	2.6	1.6	14.7	15.6	13.8
Other acute	0.5	0.6	0.4	1.0	1.3	0.8	10.0	9.8	9.5
Aleukemic, subleuk & NOS	0.4	0.5	0.3	1.0	1.3	0.8	21.7	23.3	20.1
Ill-defined & unspecified	11.3	12.9	10.2	14.6	18.1	12.1	14.3	16.8	12.0

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population by 5-year age groups. Survival rates are expressed as percents.

<sup>a</sup> SEER 12 areas.

<sup>b</sup> NCHS public use data file.

<sup>c</sup> SEER 9 areas.

<sup>d</sup> Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

- Statistic could not be calculated.

Table I-6  
AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES  
By Primary Cancer Site, Sex and Time Period

Blacks									
Site	Total	Incidence <sup>a</sup> (1996-2000)		Total	US Mortality <sup>b</sup> (1996-2000)		Total	Survival <sup>c</sup> (1992-1999)	
		Males	Females		Males	Females		Males	Females
All Sites	521.7	696.8	406.3	257.1	356.2	198.6	53.3	55.0	51.5
Oral Cavity & Pharynx:	12.5	20.5	6.4	4.5	7.9	2.0	36.1	30.7	50.6
Lip	-	-	-	-	-	-	-	-	-
Tongue	2.7	4.5	1.4	0.9	1.6	0.4	34.4	30.8	43.6
Salivary gland	0.9	1.2	0.8	0.2	0.3	0.1	76.1	63.5	89.0
Floor of mouth	1.3	2.1	0.6	0.1	0.2	0.1	35.6	32.1	48.2
Gum & other	2.1	3.1	1.4	0.6	1.0	0.4	38.1	26.4	62.5
oral cavity									
Nasopharynx	0.7	1.0	0.4	0.3	0.5	0.2	43.8	42.5	46.4
Tonsil	1.9	3.4	0.7	0.4	0.7	0.2	33.7	31.8	40.7
Oropharynx	0.7	1.2	-	0.4	0.8	0.2	27.0	28.6	-
Hypopharynx	1.5	2.8	0.5	0.3	0.5	0.1	20.5	19.5	25.0
Other oral cavity & pharynx	0.5	1.0	-	1.2	2.2	0.4	14.9	16.4	-
Digestive System:	114.9	141.6	96.3	68.1	89.2	53.9	34.6	31.9	37.5
Esophagus	7.2	11.4	4.2	7.0	12.2	3.4	9.0	9.0	8.8
Stomach	14.0	19.9	9.9	9.4	14.0	6.5	20.5	19.4	22.3
Small intestine	3.0	3.6	2.6	0.6	0.7	0.5	46.6	44.0	50.0
Colon & Rectum:	62.6	72.4	56.2	28.5	34.6	24.6	53.4	53.4	53.4
Colon	48.4	54.4	44.7	25.0	30.0	21.9	53.2	53.9	52.7
Rectum	14.2	18.0	11.5	3.5	4.7	2.7	53.8	52.1	55.8
Anus, anal canal & anorectum	1.5	1.7	1.3	0.2	0.2	0.2	50.5	39.7	63.3
Liver & Intrahep:	6.9	11.0	3.9	6.1	9.3	3.7	4.9	4.2	6.0
Liver	6.3	10.2	3.4	5.3	8.4	3.0	5.1	4.4	6.4
Intrahep bile duct	0.6	0.8	0.4	0.8	0.9	0.7	0.0	0.0	0.0
Gallbladder	1.3	0.8	1.6	0.9	0.6	1.0	12.8	13.7	12.3
Other biliary	1.2	1.6	1.1	0.5	0.5	0.4	20.8	11.0	27.1
Pancreas	15.9	18.0	14.3	14.4	16.4	12.9	3.6	3.7	3.6
Retroperitoneum	0.4	0.5	0.4	0.1	0.1	0.1	43.8	45.7	42.9
Peritoneum, omentum & mesentery	0.4	-	0.6	0.1	0.1	0.2	38.1	-	27.2
Other digestive system	0.5	0.6	0.4	0.4	0.5	0.3	3.5	3.9	0.0
Respiratory System:	89.4	134.9	58.4	69.7	113.4	41.2	16.1	15.7	16.7
Nose, nasal cavity & middle ear	0.8	1.1	0.6	0.2	0.3	0.2	37.1	36.3	37.6
Larynx	6.5	12.0	2.6	2.9	5.7	0.9	52.7	54.1	48.3
Lung & bronchus	81.2	120.4	54.8	66.4	107.0	40.0	12.4	11.1	14.6
Pleura	0.6	1.0	0.3	0.1	0.1	0.0	8.6	4.4	-
Trachea & other respiratory organs	0.3	0.4	-	0.1	0.2	0.1	28.8	27.7	-
Bones & joints	0.7	0.9	0.6	0.5	0.6	0.4	66.0	65.3	66.8
Soft tissue (incl heart)	3.2	3.5	2.9	1.7	1.7	1.7	63.2	61.0	65.6
Skin (ex basal & squam):	4.4	6.9	2.4	1.1	1.6	0.8	42.0	33.5	76.8
Melanoma of the skin	1.1	1.5	0.8	0.5	0.5	0.5	64.4	63.9	64.3
Other non-epithelial skin	3.3	5.4	1.6	0.6	1.1	0.3	38.7	30.9	81.3
Breast	70.2	2.0	121.7	21.4	0.6	35.9	73.4	54.3	73.5
Breast (in situ)	14.7	-	25.8	-	-	-	100.0	-	100.0

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population by 5-year age groups. Survival rates are expressed as percents.

<sup>a</sup> SEER 12 areas.

<sup>b</sup> NCHS public use data file.

<sup>c</sup> SEER 9 areas.

- Statistic could not be calculated.

Table I-6 - continued  
AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES  
By Primary Cancer Site, Sex and Time Period

Blacks									
Site	Total	Incidence <sup>a</sup> (1996-2000)		Total	US Mortality <sup>b</sup> (1996-2000)		Total	Survival <sup>c</sup> (1992-1999)	
		Males	Females		Males	Females		Males	Females
Female Genital System:	26.3	-	45.7	12.7	-	21.3	58.2	-	58.2
Cervix uteri	7.0	-	12.4	3.4	-	5.9	61.0	-	61.0
Corpus uteri	10.0	-	17.2	1.9	-	3.2	61.8	-	61.8
Uterus, NOS	0.4	-	0.7	2.3	-	3.8	25.3	-	25.3
Ovary	6.9	-	11.9	4.5	-	7.4	51.5	-	51.5
Vagina	0.6	-	1.0	0.2	-	0.4	45.4	-	45.4
Vulva	1.0	-	1.7	0.2	-	0.3	67.9	-	67.9
Other female genital system	0.4	-	0.7	0.2	-	0.3	62.8	-	62.8
Male Genital System:	112.3	274.9	-	25.6	73.4	-	93.3	93.3	-
Prostate	111.1	272.1	-	25.4	73.0	-	93.4	93.4	-
Testis	0.7	1.4	-	0.1	0.2	-	86.9	86.9	-
Penis	0.4	1.0	-	0.1	0.3	-	70.3	70.3	-
Other male genital system	0.2	0.4	-	-	-	-	-	-	-
Urinary System:	26.3	39.4	17.6	8.3	12.2	5.9	62.0	64.9	57.7
Urinary bladder	12.6	20.4	7.6	4.0	5.8	3.0	64.0	70.1	52.9
Kidney & renal pelvis	12.9	17.7	9.4	4.2	6.2	2.8	60.7	59.9	61.7
Ureter	0.2	-	-	0.1	-	0.1	-	-	-
Other urinary system	0.6	0.8	0.5	0.1	0.1	0.2	63.6	81.6	39.9
Eye & Orbit	0.2	-	-	0.0	0.0	0.0	88.5	-	89.0
Brain & Nervous System: <sup>d</sup>	4.0	4.8	3.4	2.7	3.3	2.3	38.6	40.1	36.9
Brain	3.6	4.4	2.9	-	-	-	36.9	39.2	34.3
Cranial nerves & other nervous system	0.4	0.4	0.5	-	-	-	55.1	50.1	58.6
Endocrine System:	4.6	2.7	6.2	0.8	0.7	0.9	89.2	81.6	91.8
Thyroid	3.9	2.0	5.6	0.5	0.3	0.5	93.9	87.6	95.0
Other endocrine & thymus	0.7	0.7	0.7	0.4	0.4	0.3	64.5	64.8	63.2
Lymphoma:	17.0	21.4	13.6	6.3	8.2	5.0	53.5	47.9	61.8
Hodgkin lymphoma	2.4	2.8	2.0	0.5	0.6	0.3	77.5	73.5	81.7
Non-Hodgkin lymphoma	14.6	18.6	11.6	5.9	7.6	4.6	47.1	42.3	54.9
Myeloma	11.2	12.9	10.2	7.6	9.2	6.6	33.3	34.8	32.0
Leukemia:	9.9	13.0	7.8	7.0	9.3	5.5	39.2	38.5	40.1
Lymphocytic:	4.0	5.6	2.8	2.1	3.0	1.5	57.4	54.6	61.6
Acute lymphocytic	0.9	1.0	0.7	0.4	0.5	0.3	59.8	56.6	63.0
Chronic lymphocytic	2.9	4.3	1.9	1.6	2.3	1.1	57.7	55.3	61.4
Other lymphocytic	0.2	-	-	0.1	0.2	0.1	45.1	-	-
Myeloid & Monocytic:	5.2	6.5	4.4	3.0	3.8	2.5	26.0	25.5	26.6
Acute myeloid	3.2	4.0	2.8	2.0	2.5	1.7	20.8	22.0	19.0
Chronic myeloid	1.6	2.2	1.2	0.9	1.1	0.7	35.4	31.4	41.1
Acute monocytic	0.2	-	-	0.0	-	-	-	-	-
Other myeloid & monocytic	0.2	-	-	0.1	0.2	0.1	33.4	-	-
Other:	0.7	0.9	0.6	1.9	2.5	1.5	23.2	18.6	27.6
Other acute	0.4	0.5	-	0.8	1.0	0.6	15.0	11.3	-
Aleukemic, subleuk & NOS	0.4	-	0.4	1.1	1.5	0.9	29.7	25.5	30.5
Ill-defined & unspecified	14.5	17.1	12.8	19.0	24.7	15.2	10.5	10.4	10.6

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population by 5-year age groups. Survival rates are expressed as percents.

<sup>a</sup> SEER 12 areas.

<sup>b</sup> NCHS public use data file.

<sup>c</sup> SEER 9 areas.

<sup>d</sup> Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

- Statistic could not be calculated.

Table I-7

## MESOTHELIOMAS (Invasive)

AGE-ADJUSTED SEER CANCER INCIDENCE RATES<sup>a</sup>, 1977-2000

By Race, Sex and Year of Diagnosis

Race/Sex	Year of Diagnosis													
	1977- 1978	1979- 1980	1981- 1982	1983- 1984	1985- 1986	1987- 1988	1989- 1990	1991- 1992	1993- 1994	1995- 1996	1997- 1998	1999- 2000		
All Races														
Both Sexes	0.7	0.9	0.8	1.1	0.9	1.0	1.1	1.2	1.1	1.2	1.0	1.1		
Males	1.2	1.7	1.4	2.0	1.7	1.8	2.2	2.3	2.1	2.1	2.0	2.1		
0-54	0.3	0.3	0.3	0.3	0.2	0.3	0.3	0.2	0.3	0.2	0.2	0.1		
55-64	2.8	3.3	3.6	3.9	4.3	3.0	3.9	4.5	3.2	3.7	3.4	3.5		
65-74	5.5	8.9	6.2	8.7	7.9	9.2	11.4	10.0	10.2	10.2	9.8	9.4		
75-84	6.3	9.9	8.7	15.2	11.4	12.9	14.2	17.6	16.4	17.3	14.4	18.2		
85+	3.4	8.0	4.6	8.9	6.5	8.9	13.7	18.2	12.3	14.4	17.0	14.9		
Females	0.3	0.3	0.3	0.4	0.4	0.4	0.4	0.4	0.4	0.5	0.4	0.4		
0-54	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1		
55-64	0.7	1.1	0.7	0.9	1.1	0.5	1.0	0.8	1.2	0.9	0.3	0.6		
65-74	0.8	1.6	1.4	1.5	1.9	1.1	1.7	1.3	1.4	1.6	1.7	1.2		
75-84	1.3	0.9	1.9	3.0	2.3	2.3	2.0	2.8	2.7	2.7	2.2	2.4		
85+	0.0	1.0	0.6	1.2	0.6	2.7	1.3	2.1	1.5	2.9	1.7	2.0		
Whites														
Both Sexes	0.7	0.9	0.9	1.1	1.0	1.0	1.2	1.3	1.2	1.3	1.1	1.2		
Males	1.3	1.8	1.5	2.1	1.8	1.9	2.3	2.5	2.3	2.3	2.1	2.3		
Females	0.3	0.3	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.5	0.4	0.4		
Blacks														
Both Sexes	0.2	0.5	0.3	0.6	0.7	0.6	0.7	0.7	0.9	0.6	0.8	0.6		
Males	0.3	0.8	0.8	1.2	1.4	1.1	1.2	1.5	1.6	1.3	1.4	1.1		
Females	0.2	0.2	0.0	0.2	0.2	0.4	0.4	0.2	0.4	0.2	0.4	0.2		

<sup>a</sup> SEER 9 areas. Rates are per 100,000 and are age-adjusted to the 2000 U.S. standard by 5-year age groups.

Table I-8  
SEER INCIDENCE AND U.S. MORTALITY TRENDS BY PRIMARY CANCER SITE AND SEX  
All Races, 1992-2000

Site	Incidence <sup>a</sup>			US Mortality <sup>b</sup>		
	Total APC	Males APC	Females APC	Total APC	Males APC	Females APC
All Sites	-0.7 <sup>c</sup>	-1.7 <sup>c</sup>	0.2	-1.0 <sup>c</sup>	-1.4 <sup>c</sup>	-0.7 <sup>c</sup>
Oral Cavity & Pharynx:	-2.0 <sup>c</sup>	-2.3 <sup>c</sup>	-1.5 <sup>c</sup>	-2.7 <sup>c</sup>	-3.0 <sup>c</sup>	-2.5 <sup>c</sup>
Lip	-4.5 <sup>c</sup>	-5.5 <sup>c</sup>	-1.9	-5.9 <sup>c</sup>	-6.7 <sup>c</sup>	-5.4
Tongue	-0.3	-0.5	-0.2	-2.0 <sup>c</sup>	-2.5 <sup>c</sup>	-1.4 <sup>c</sup>
Salivary gland	0.9	0.8	0.9	-2.0 <sup>c</sup>	-2.1 <sup>c</sup>	-2.0 <sup>c</sup>
Floor of mouth	-5.0 <sup>c</sup>	-5.9 <sup>c</sup>	-3.1	-8.7 <sup>c</sup>	-9.0 <sup>c</sup>	-8.6 <sup>c</sup>
Gum & other	-3.7 <sup>c</sup>	-4.6 <sup>c</sup>	-2.3 <sup>c</sup>	-3.5 <sup>c</sup>	-4.3 <sup>c</sup>	-2.7 <sup>c</sup>
oral cavity						
Nasopharynx	-1.2	-1.7	-0.5	-2.4 <sup>c</sup>	-2.5 <sup>c</sup>	-2.4 <sup>c</sup>
Tonsil	0.5	2.0 <sup>c</sup>	-4.5 <sup>c</sup>	-2.3 <sup>c</sup>	-2.4 <sup>c</sup>	-2.9 <sup>c</sup>
Oropharynx	-1.6	-2.0	-0.3	-0.5	-0.6	-0.5
Hypopharynx	-2.9 <sup>c</sup>	-3.0 <sup>c</sup>	-3.5	-4.9 <sup>c</sup>	-5.4 <sup>c</sup>	-3.8
Other oral cavity & pharynx	-5.8 <sup>c</sup>	-6.5 <sup>c</sup>	-4.7 <sup>c</sup>	-2.3 <sup>c</sup>	-2.1 <sup>c</sup>	-3.0 <sup>c</sup>
Digestive System:	-0.2	-0.5	-0.1	-0.9 <sup>c</sup>	-1.0 <sup>c</sup>	-1.0 <sup>c</sup>
Esophagus	0.3	0.4	-0.4	0.6 <sup>c</sup>	0.6 <sup>c</sup>	0.1
Stomach	-1.3 <sup>c</sup>	-1.9 <sup>c</sup>	-0.5	-2.8 <sup>c</sup>	-3.2 <sup>c</sup>	-2.5 <sup>c</sup>
Small intestine	0.8	-0.1	2.1	-1.0	-0.4	-1.5 <sup>c</sup>
Colon & Rectum:	-0.6	-0.9 <sup>c</sup>	-0.3	-1.7 <sup>c</sup>	-2.0 <sup>c</sup>	-1.7 <sup>c</sup>
Colon	-0.7 <sup>c</sup>	-1.1 <sup>c</sup>	-0.4	-1.9 <sup>c</sup>	-2.1 <sup>c</sup>	-1.8 <sup>c</sup>
Rectum	-0.2	-0.4	0.0	-0.8 <sup>c</sup>	-1.0 <sup>c</sup>	-0.8 <sup>c</sup>
Anus, anal canal & anorectum	1.8 <sup>c</sup>	2.4	1.4	0.7	0.8	0.8
Liver & Intrahep:	3.9 <sup>c</sup>	3.7 <sup>c</sup>	3.7 <sup>c</sup>	2.1 <sup>c</sup>	2.2 <sup>c</sup>	1.4 <sup>c</sup>
Liver	4.3 <sup>c</sup>	4.0 <sup>c</sup>	4.4 <sup>c</sup>	1.7 <sup>c</sup>	1.9 <sup>c</sup>	0.4
Intrahep bile duct	1.8	1.8	1.3	3.9 <sup>c</sup>	3.2 <sup>c</sup>	4.5 <sup>c</sup>
Gallbladder	-2.6 <sup>c</sup>	-2.6	-2.3 <sup>c</sup>	-2.4 <sup>c</sup>	-1.7 <sup>c</sup>	-2.4 <sup>c</sup>
Other biliary	-0.6	-0.5	-0.7	-3.2 <sup>c</sup>	-3.4 <sup>c</sup>	-3.3 <sup>c</sup>
Pancreas	-0.4	-0.4	-0.5	-0.1	-0.3	-0.1
Retroperitoneum	-1.3	1.0	-2.9 <sup>c</sup>	-2.8 <sup>c</sup>	-2.2	-3.1 <sup>c</sup>
Peritoneum, omentum & mesentery	8.6 <sup>c</sup>	-1.6	11.0 <sup>c</sup>	7.7 <sup>c</sup>	-2.2	11.2 <sup>c</sup>
Other digestive system	1.0	-0.4	2.4	9.0 <sup>c</sup>	9.3 <sup>c</sup>	8.6 <sup>c</sup>
Respiratory System:	-1.3 <sup>c</sup>	-2.4 <sup>c</sup>	0.0	-0.8 <sup>c</sup>	-1.9 <sup>c</sup>	0.6 <sup>c</sup>
Nose, nasal cavity & middle ear	-0.5	-0.6	-1.1	-2.5 <sup>c</sup>	-2.2	-3.7 <sup>c</sup>
Larynx	-2.6 <sup>c</sup>	-3.2 <sup>c</sup>	-1.0	-2.0 <sup>c</sup>	-2.4 <sup>c</sup>	-1.4 <sup>c</sup>
Lung & bronchus	-1.2 <sup>c</sup>	-2.3 <sup>c</sup>	0.0	-0.8 <sup>c</sup>	-1.8 <sup>c</sup>	0.7 <sup>c</sup>
Pleura	-1.0	-1.6 <sup>c</sup>	0.1	-5.9 <sup>c</sup>	-5.6 <sup>c</sup>	-7.4 <sup>c</sup>
Trachea & other respiratory organs	-3.1 <sup>c</sup>	-5.1 <sup>c</sup>	-0.1	-4.7 <sup>c</sup>	-5.3 <sup>c</sup>	-3.9 <sup>c</sup>
Bones & joints	-1.4	-1.6	-1.1	-1.0 <sup>c</sup>	-1.0 <sup>c</sup>	-1.2 <sup>c</sup>
Soft tissue (incl heart)	1.3 <sup>c</sup>	1.0	1.7	-0.9	-0.5	-1.4
Skin (ex basal & squam):	-0.5	-1.7 <sup>c</sup>	2.1 <sup>c</sup>	-0.4 <sup>c</sup>	-0.3	-0.6
Melanoma of the skin	2.5 <sup>c</sup>	2.8 <sup>c</sup>	2.3 <sup>c</sup>	-0.1	0.2	-0.5
Other non-epithelial skin	-11.9 <sup>c</sup>	-14.4 <sup>c</sup>	0.8	-1.3	-1.4	-1.0
Breast	0.6 <sup>c</sup>	1.1	0.8 <sup>c</sup>	-2.5 <sup>c</sup>	0.4	-2.4 <sup>c</sup>
Breast (in situ)	6.5 <sup>c</sup>	7.3	6.6 <sup>c</sup>	-	-	-

- <sup>a</sup> The APC is the Annual Percent Change over the time interval.  
SEER 12 areas. Rates are per 100,000 and are age-adjusted to the 2000 U. S. standard population by 5-year age groups.
- <sup>b</sup> NCHS public use data file. Rates are per 100,000 and are age-adjusted to the 2000 U. S. standard population by 5-year age groups.
- <sup>c</sup> The APC is significantly different from zero (p<.05).
- Statistic could not be calculated.

Table I-8 - continued  
SEER INCIDENCE AND U.S. MORTALITY TRENDS BY PRIMARY CANCER SITE AND SEX  
All Races, 1992-2000

Site	Incidence <sup>a</sup>			US Mortality <sup>b</sup>		
	Total APC	Males APC	Females APC	Total APC	Males APC	Females APC
Female Genital System:	-0.9 <sup>c</sup>	-	-0.7 <sup>c</sup>	-1.2 <sup>c</sup>	-	-1.0 <sup>c</sup>
Cervix uteri	-2.6 <sup>c</sup>	-	-2.5 <sup>c</sup>	-3.1 <sup>c</sup>	-	-2.9 <sup>c</sup>
Corpus uteri	-0.3	-	-0.1	-1.7 <sup>c</sup>	-	-1.4 <sup>c</sup>
Uterus, NOS	0.2	-	0.6	0.5	-	0.8
Ovary	-1.0 <sup>c</sup>	-	-0.8 <sup>c</sup>	-1.0 <sup>c</sup>	-	-0.8 <sup>c</sup>
Vagina	-1.5	-	-1.2	-1.2	-	-0.9
Vulva	0.5	-	1.0	-0.6	-	-0.4
Other female genital system	-1.6	-	-1.5	3.6	-	3.6
Male Genital System:	-2.3	-3.0 <sup>c</sup>	-	-3.1 <sup>c</sup>	-3.4 <sup>c</sup>	-
Prostate	-2.4	-3.1 <sup>c</sup>	-	-3.1 <sup>c</sup>	-3.4 <sup>c</sup>	-
Testis	1.3 <sup>c</sup>	1.3 <sup>c</sup>	-	-0.8	-1.0	-
Penis	-2.5	-2.6	-	-0.8	-1.1	-
Other male genital system	1.4	1.3	-	3.7	3.7	-
Urinary System:	0.3 <sup>c</sup>	0.2	0.3	-0.3 <sup>c</sup>	-0.4 <sup>c</sup>	-0.5
Urinary bladder	-0.1	-0.1	-0.5	-0.3 <sup>c</sup>	-0.6 <sup>c</sup>	-0.5
Kidney & renal pelvis	1.3 <sup>c</sup>	1.1 <sup>c</sup>	1.3 <sup>c</sup>	-0.3	-0.2	-0.5
Ureter	-1.2	-1.8	0.0	-1.2	-1.9 <sup>c</sup>	-0.5
Other urinary system	-0.3	-0.3	-0.1	5.7	9.3 <sup>c</sup>	2.5
Eye & Orbit	-1.5	-2.1	-1.3	-2.9 <sup>c</sup>	-3.1 <sup>c</sup>	-2.8
Brain & Nervous System: <sup>d</sup>	-0.5	-0.6	-0.5	-0.7 <sup>c</sup>	-0.6 <sup>c</sup>	-0.8 <sup>c</sup>
Brain	-0.4	-0.4	-0.5	-	-	-
Cranial nerves & other nervous system	-1.9	-2.9	-0.9	-	-	-
Endocrine System:	3.1 <sup>c</sup>	1.3 <sup>c</sup>	3.9 <sup>c</sup>	0.0	0.9	-0.6
Thyroid	3.4 <sup>c</sup>	1.8 <sup>c</sup>	4.0 <sup>c</sup>	0.4	2.4 <sup>c</sup>	-0.4
Other endocrine & thymus	0.3	-0.7	1.1	-0.6	-0.6	-0.8
Lymphoma:	0.0	-0.5	0.7	-0.2	-0.2	-0.2
Hodgkin lymphoma	-0.4	-0.1	-0.6	-3.7 <sup>c</sup>	-4.2 <sup>c</sup>	-3.0 <sup>c</sup>
Non-Hodgkin lymphoma	0.0	-0.5	0.9 <sup>c</sup>	0.0	0.1	0.0
Myeloma	-0.7	-0.8	-0.9	-0.3	-0.5	-0.1
Leukemia:	-1.3 <sup>c</sup>	-1.5 <sup>c</sup>	-1.0	-0.5 <sup>c</sup>	-0.7 <sup>c</sup>	-0.5 <sup>c</sup>
Lymphocytic:	-2.5 <sup>c</sup>	-2.9 <sup>c</sup>	-2.0 <sup>c</sup>	-1.2 <sup>c</sup>	-1.5 <sup>c</sup>	-1.1 <sup>c</sup>
Acute lymphocytic	0.5	-0.8	2.1	-1.5 <sup>c</sup>	-1.7 <sup>c</sup>	-1.5 <sup>c</sup>
Chronic lymphocytic	-3.8 <sup>c</sup>	-3.7 <sup>c</sup>	-4.3 <sup>c</sup>	-0.9	-1.2 <sup>c</sup>	-0.6
Other lymphocytic	-0.4	-1.5	2.4	-3.5 <sup>c</sup>	-3.4 <sup>c</sup>	-4.0 <sup>c</sup>
Myeloid & Monocytic:	0.5	0.8	0.2	0.4 <sup>c</sup>	0.4	0.4 <sup>c</sup>
Acute myeloid	1.6 <sup>c</sup>	1.8 <sup>c</sup>	1.3 <sup>c</sup>	1.8 <sup>c</sup>	1.7 <sup>c</sup>	1.9 <sup>c</sup>
Chronic myeloid	-1.9 <sup>c</sup>	-1.5	-2.5 <sup>c</sup>	-4.1 <sup>c</sup>	-4.2 <sup>c</sup>	-4.2 <sup>c</sup>
Acute monocytic	2.8	3.9	1.7	-7.1 <sup>c</sup>	-5.2 <sup>c</sup>	-9.4 <sup>c</sup>
Other myeloid & monocytic	-1.3	-2.5	0.7	8.4	9.7	6.6
Other:	-4.6 <sup>c</sup>	-6.0 <sup>c</sup>	-2.8	-1.3 <sup>c</sup>	-1.4 <sup>c</sup>	-1.3 <sup>c</sup>
Other acute	-5.9 <sup>c</sup>	-7.6 <sup>c</sup>	-3.9	-3.2 <sup>c</sup>	-3.2 <sup>c</sup>	-3.4 <sup>c</sup>
Aleukemic, subleuk & NOS	-2.9 <sup>c</sup>	-3.7	-1.2	0.8 <sup>c</sup>	0.5	1.0 <sup>c</sup>
Ill-defined & unspecified	-3.1 <sup>c</sup>	-3.4 <sup>c</sup>	-2.9 <sup>c</sup>	0.7	0.7	0.6

- <sup>a</sup> The APC is the Annual Percent Change over the time interval.  
SEER 12 areas. Rates are per 100,000 and are age-adjusted to the 2000 U. S. standard population by 5-year age groups.
- <sup>b</sup> NCHS public use data file. Rates are per 100,000 and are age-adjusted to the 2000 U. S. standard population by 5-year age groups.
- <sup>c</sup> The APC is significantly different from zero (p<.05).
- <sup>d</sup> Due to coding changes, Brain & Nervous System mortality are no longer shown separately.
- Statistic could not be calculated.

Table I-9  
SEER INCIDENCE AND U.S. MORTALITY TRENDS BY PRIMARY CANCER SITE AND SEX  
Whites, 1992-2000

Site	Incidence <sup>a</sup>			US Mortality <sup>b</sup>		
	Total APC	Males APC	Females APC	Total APC	Males APC	Females APC
All Sites	-0.6 <sup>c</sup>	-1.8 <sup>c</sup>	0.4	-0.9 <sup>c</sup>	-1.3 <sup>c</sup>	-0.6 <sup>c</sup>
Oral Cavity & Pharynx:	-1.9 <sup>c</sup>	-2.2 <sup>c</sup>	-1.7 <sup>c</sup>	-2.4 <sup>c</sup>	-2.7 <sup>c</sup>	-2.3 <sup>c</sup>
Lip	-4.6 <sup>c</sup>	-5.6 <sup>c</sup>	-1.8	-5.8 <sup>c</sup>	-6.7 <sup>c</sup>	-5.5
Tongue	-0.2	-0.1	-1.0	-1.4 <sup>c</sup>	-1.9 <sup>c</sup>	-0.8
Salivary gland	1.3	1.1	1.3	-2.0 <sup>c</sup>	-2.1 <sup>c</sup>	-2.0
Floor of mouth	-4.8 <sup>c</sup>	-5.8 <sup>c</sup>	-3.0	-8.5 <sup>c</sup>	-8.8 <sup>c</sup>	-8.6 <sup>c</sup>
Gum & other oral cavity	-3.9 <sup>c</sup>	-4.8 <sup>c</sup>	-2.5 <sup>c</sup>	-3.2 <sup>c</sup>	-4.1 <sup>c</sup>	-2.5 <sup>c</sup>
Nasopharynx	-1.4	-1.5	-2.1	-3.1 <sup>c</sup>	-2.8 <sup>c</sup>	-3.8 <sup>c</sup>
Tonsil	0.8	2.3 <sup>c</sup>	-4.3 <sup>c</sup>	-1.4 <sup>c</sup>	-1.5	-2.5 <sup>c</sup>
Oropharynx	-2.1	-3.0	0.0	-0.2	-0.5	0.2
Hypopharynx	-2.4 <sup>c</sup>	-2.6	-2.8	-4.9 <sup>c</sup>	-5.4 <sup>c</sup>	-3.9 <sup>c</sup>
Other oral cavity & pharynx	-5.7 <sup>c</sup>	-6.9 <sup>c</sup>	-3.5	-2.2 <sup>c</sup>	-2.0 <sup>c</sup>	-2.9 <sup>c</sup>
Digestive System:	-0.2	-0.5	-0.1	-0.9 <sup>c</sup>	-1.0 <sup>c</sup>	-1.0 <sup>c</sup>
Esophagus	1.5 <sup>c</sup>	1.8 <sup>c</sup>	0.1	1.7 <sup>c</sup>	1.7 <sup>c</sup>	0.9 <sup>c</sup>
Stomach	-1.5 <sup>c</sup>	-2.1 <sup>c</sup>	-0.8	-3.1 <sup>c</sup>	-3.5 <sup>c</sup>	-2.8 <sup>c</sup>
Small intestine	0.5	-0.2	1.3	-1.0	-0.3	-1.6 <sup>c</sup>
Colon & Rectum:	-0.6	-1.0 <sup>c</sup>	-0.3	-1.8 <sup>c</sup>	-2.1 <sup>c</sup>	-1.8 <sup>c</sup>
Colon	-0.8 <sup>c</sup>	-1.2 <sup>c</sup>	-0.5	-2.0 <sup>c</sup>	-2.3 <sup>c</sup>	-1.9 <sup>c</sup>
Rectum	-0.2	-0.5	0.1	-0.7 <sup>c</sup>	-1.0 <sup>c</sup>	-0.6 <sup>c</sup>
Anus, anal canal & anorectum	2.5 <sup>c</sup>	3.2 <sup>c</sup>	2.0	1.0	1.2	1.2
Liver & Intrahep:	4.5 <sup>c</sup>	4.1 <sup>c</sup>	4.5 <sup>c</sup>	2.1 <sup>c</sup>	2.2 <sup>c</sup>	1.4 <sup>c</sup>
Liver	5.1 <sup>c</sup>	4.6 <sup>c</sup>	5.2 <sup>c</sup>	1.6 <sup>c</sup>	1.9 <sup>c</sup>	0.2
Intrahep bile duct	2.3 <sup>c</sup>	1.8	2.4	4.0 <sup>c</sup>	3.3 <sup>c</sup>	4.4 <sup>c</sup>
Gallbladder	-2.7 <sup>c</sup>	-2.0	-2.6 <sup>c</sup>	-2.5 <sup>c</sup>	-1.9 <sup>c</sup>	-2.5 <sup>c</sup>
Other biliary	-0.4	-0.4	-0.5	-3.1 <sup>c</sup>	-3.3 <sup>c</sup>	-3.1 <sup>c</sup>
Pancreas	-0.3	-0.2	-0.5	0.0	-0.1	0.0
Retroperitoneum	-0.4	2.1 <sup>c</sup>	-2.5	-2.8 <sup>c</sup>	-2.9	-2.4
Peritoneum, omentum & mesentery	8.6 <sup>c</sup>	-3.5	11.5 <sup>c</sup>	7.8 <sup>c</sup>	-2.8	11.5 <sup>c</sup>
Other digestive system	0.7	-0.8	2.1	9.3 <sup>c</sup>	9.4 <sup>c</sup>	8.9 <sup>c</sup>
Respiratory System:	-1.2 <sup>c</sup>	-2.3 <sup>c</sup>	0.1	-0.7 <sup>c</sup>	-1.8 <sup>c</sup>	0.7 <sup>c</sup>
Nose, nasal cavity & middle ear	-0.3	-0.3	-0.8	-2.1 <sup>c</sup>	-1.5	-3.6 <sup>c</sup>
Larynx	-2.4 <sup>c</sup>	-3.1 <sup>c</sup>	-0.7	-1.8 <sup>c</sup>	-2.3 <sup>c</sup>	-1.1
Lung & bronchus	-1.1 <sup>c</sup>	-2.3 <sup>c</sup>	0.1	-0.6 <sup>c</sup>	-1.7 <sup>c</sup>	0.7 <sup>c</sup>
Pleura	-0.8	-1.4	0.2	-5.8 <sup>c</sup>	-5.5 <sup>c</sup>	-7.8 <sup>c</sup>
Trachea & other respiratory organs	-3.5	-5.4 <sup>c</sup>	-1.6	-4.1 <sup>c</sup>	-5.1 <sup>c</sup>	-2.9
Bones & joints	-1.0	-1.8 <sup>c</sup>	0.0	-0.7 <sup>c</sup>	-0.8	-0.6
Soft tissue (incl heart)	1.2 <sup>c</sup>	0.7	1.9 <sup>c</sup>	-0.6	-0.4	-1.0
Skin (ex basal & squam):	0.0	-1.3 <sup>c</sup>	2.7 <sup>c</sup>	-0.2	-0.1	-0.3
Melanoma of the skin	3.0 <sup>c</sup>	3.1 <sup>c</sup>	2.9 <sup>c</sup>	0.0	0.3	-0.3
Other non-epithelial skin	-12.8 <sup>c</sup>	-15.3 <sup>c</sup>	1.1	-0.8	-1.0	-0.4
Breast	0.7 <sup>c</sup>	1.9	0.9 <sup>c</sup>	-2.7 <sup>c</sup>	0.3	-2.6 <sup>c</sup>
Breast (in situ)	6.4 <sup>c</sup>	9.4 <sup>c</sup>	6.5 <sup>c</sup>	-	-	-

- <sup>a</sup> The APC is the Annual Percent Change over the time interval.  
SEER 12 areas. Rates are per 100,000 and are age-adjusted to the 2000 U. S. standard population by 5-year age groups.
- <sup>b</sup> NCHS public use data file. Rates are per 100,000 and are age-adjusted to the 2000 U. S. standard population by 5-year age groups.
- <sup>c</sup> The APC is significantly different from zero (p<.05).
- Statistic could not be calculated.



Table I-9 - continued  
SEER INCIDENCE AND U.S. MORTALITY TRENDS BY PRIMARY CANCER SITE AND SEX  
Whites, 1992-2000

Site	Incidence <sup>a</sup>			US Mortality <sup>b</sup>		
	Total APC	Males APC	Females APC	Total APC	Males APC	Females APC
Female Genital System:	-0.8 <sup>c</sup>	-	-0.5 <sup>c</sup>	-1.0 <sup>c</sup>	-	-0.8 <sup>c</sup>
Cervix uteri	-2.2 <sup>c</sup>	-	-2.1 <sup>c</sup>	-2.6 <sup>c</sup>	-	-2.4 <sup>c</sup>
Corpus uteri	-0.3	-	0.0	-1.8 <sup>c</sup>	-	-1.5 <sup>c</sup>
Uterus, NOS	1.0	-	1.7	0.4	-	0.8
Ovary	-0.9 <sup>c</sup>	-	-0.7 <sup>c</sup>	-0.9 <sup>c</sup>	-	-0.7 <sup>c</sup>
Vagina	-1.1	-	-0.7	-1.1	-	-0.6
Vulva	1.1	-	1.7	-0.4	-	-0.1
Other female genital system	-1.4	-	-1.4	3.6	-	3.6
Male Genital System:	-2.5	-3.3 <sup>c</sup>	-	-3.2 <sup>c</sup>	-3.5 <sup>c</sup>	-
Prostate	-2.6	-3.4 <sup>c</sup>	-	-3.2 <sup>c</sup>	-3.5 <sup>c</sup>	-
Testis	1.4 <sup>c</sup>	1.3 <sup>c</sup>	-	-0.9	-1.1	-
Penis	-2.7	-3.1	-	-0.1	-0.3	-
Other male genital system	-0.1	-0.4	-	4.0	3.5	-
Urinary System:	0.5 <sup>c</sup>	0.3	0.3	-0.2	-0.3 <sup>c</sup>	-0.4
Urinary bladder	0.0	0.0	-0.4 <sup>c</sup>	-0.2	-0.4 <sup>c</sup>	-0.4
Kidney & renal pelvis	1.4 <sup>c</sup>	1.3 <sup>c</sup>	1.3 <sup>c</sup>	-0.2	-0.3	-0.5
Ureter	-1.0	-1.3	-0.3	-1.0	-1.6	-0.5
Other urinary system	0.5	-0.3	2.1	7.3 <sup>c</sup>	11.0 <sup>c</sup>	3.6
Eye & Orbit	-1.3	-2.1	-0.9	-3.0 <sup>c</sup>	-3.3 <sup>c</sup>	-2.9
Brain & Nervous System: <sup>d</sup>	-0.3	-0.4	-0.2	-0.6 <sup>c</sup>	-0.5 <sup>c</sup>	-0.7 <sup>c</sup>
Brain	-0.1	-0.2	-0.1	-	-	-
Cranial nerves & other nervous system	-2.1	-3.2	-1.3	-	-	-
Endocrine System:	3.5 <sup>c</sup>	1.9 <sup>c</sup>	4.3 <sup>c</sup>	-0.1	1.0	-0.8
Thyroid	3.8 <sup>c</sup>	2.3 <sup>c</sup>	4.5 <sup>c</sup>	0.2	2.3 <sup>c</sup>	-0.7
Other endocrine & thymus	0.8	0.3	1.3	-0.7	-0.5	-1.0
Lymphoma:	0.0	-0.5	0.7	-0.1	-0.1	-0.1
Hodgkin lymphoma	-0.1	-0.1	-0.1	-3.6 <sup>c</sup>	-3.9 <sup>c</sup>	-3.0 <sup>c</sup>
Non-Hodgkin lymphoma	0.0	-0.5	0.9 <sup>c</sup>	0.1	0.1	0.0
Myeloma	-0.6	-0.4	-1.2	-0.3	-0.3	-0.3
Leukemia:	-1.2 <sup>c</sup>	-1.6 <sup>c</sup>	-0.7	-0.4 <sup>c</sup>	-0.6 <sup>c</sup>	-0.4
Lymphocytic:	-2.3 <sup>c</sup>	-3.0 <sup>c</sup>	-1.5	-1.1 <sup>c</sup>	-1.3 <sup>c</sup>	-1.0 <sup>c</sup>
Acute lymphocytic	1.0	-0.8	3.5 <sup>c</sup>	-1.3 <sup>c</sup>	-1.5 <sup>c</sup>	-1.2
Chronic lymphocytic	-3.8 <sup>c</sup>	-3.9 <sup>c</sup>	-4.2 <sup>c</sup>	-0.7	-1.0 <sup>c</sup>	-0.6
Other lymphocytic	-0.4	-1.6	2.7	-3.6 <sup>c</sup>	-3.6 <sup>c</sup>	-4.1 <sup>c</sup>
Myeloid & Monocytic:	0.5	0.6	0.3	0.5 <sup>c</sup>	0.4	0.5 <sup>c</sup>
Acute myeloid	1.7 <sup>c</sup>	1.7 <sup>c</sup>	1.5 <sup>c</sup>	1.9 <sup>c</sup>	1.8 <sup>c</sup>	2.0 <sup>c</sup>
Chronic myeloid	-2.0 <sup>c</sup>	-1.6	-2.6 <sup>c</sup>	-4.2 <sup>c</sup>	-4.3 <sup>c</sup>	-4.1 <sup>c</sup>
Acute monocytic	2.9	3.4	3.0	-7.2 <sup>c</sup>	-5.2 <sup>c</sup>	-9.8 <sup>c</sup>
Other myeloid & monocytic	-1.7	-1.7	-1.2	8.6	9.9	6.6
Other:	-4.1 <sup>c</sup>	-5.8 <sup>c</sup>	-1.9	-1.2 <sup>c</sup>	-1.4 <sup>c</sup>	-1.3 <sup>c</sup>
Other acute	-5.3 <sup>c</sup>	-7.3 <sup>c</sup>	-2.8	-3.2 <sup>c</sup>	-3.1 <sup>c</sup>	-3.5 <sup>c</sup>
Aleukemic, subleuk & NOS	-2.3	-3.6 <sup>c</sup>	-0.5	1.0 <sup>c</sup>	0.5	1.4 <sup>c</sup>
Ill-defined & unspecified	-2.9 <sup>c</sup>	-3.3 <sup>c</sup>	-2.6 <sup>c</sup>	0.9	0.9	0.8

- <sup>a</sup> The APC is the Annual Percent Change over the time interval.  
SEER 12 areas. Rates are per 100,000 and are age-adjusted to the 2000 U. S. standard population by 5-year age groups.
- <sup>b</sup> NCHS public use data file. Rates are per 100,000 and are age-adjusted to the 2000 U. S. standard population by 5-year age groups.
- <sup>c</sup> The APC is significantly different from zero (p<.05).
- <sup>d</sup> Due to coding changes, Brain & Nervous System mortality are no longer shown separately.
- Statistic could not be calculated.

Table I-10  
SEER INCIDENCE AND U.S. MORTALITY TRENDS BY PRIMARY CANCER SITE AND SEX  
Blacks, 1992-2000

Site	Incidence <sup>a</sup>			US Mortality <sup>b</sup>		
	Total APC	Males APCAPC	Females APC	Total APC	Males APC	Females APC
All Sites	-1.0 <sup>c</sup>	-1.9 <sup>c</sup>	-0.1	-1.3 <sup>c</sup>	-1.8 <sup>c</sup>	-0.7 <sup>c</sup>
Oral Cavity & Pharynx:	-3.2 <sup>c</sup>	-3.2 <sup>c</sup>	-2.6	-4.0 <sup>c</sup>	-4.2 <sup>c</sup>	-3.1 <sup>c</sup>
Lip	-2.0	-	-	-	-	-
Tongue	-2.7	-4.0	0.5	-5.8 <sup>c</sup>	-5.9 <sup>c</sup>	-5.6 <sup>c</sup>
Salivary gland	-1.5	-0.9	-0.9	-1.0	-2.7	1.8
Floor of mouth	-5.4	-6.0	-2.1	-9.0 <sup>c</sup>	-9.1 <sup>c</sup>	-8.0 <sup>c</sup>
Gum & other	-4.2 <sup>c</sup>	-5.0	-2.2	-5.5 <sup>c</sup>	-5.5 <sup>c</sup>	-4.5
oral cavity						
Nasopharynx	-1.9	-2.0	-0.6	0.1	-1.9	4.1
Tonsil	-0.3	1.0	-2.2	-5.2 <sup>c</sup>	-5.6 <sup>c</sup>	-3.3
Oropharynx	-0.5	0.5	-4.1	-1.8	-1.4	-3.1
Hypopharynx	-6.6 <sup>c</sup>	-5.7	-8.4 <sup>c</sup>	-5.6 <sup>c</sup>	-6.2 <sup>c</sup>	-2.6
Other oral cavity & pharynx	-5.2 <sup>c</sup>	-2.5	-	-2.5 <sup>c</sup>	-2.3 <sup>c</sup>	-2.4
Digestive System:	-0.6 <sup>c</sup>	-0.9 <sup>c</sup>	-0.2	-1.1 <sup>c</sup>	-1.4 <sup>c</sup>	-0.9 <sup>c</sup>
Esophagus	-5.3 <sup>c</sup>	-6.4 <sup>c</sup>	-3.1 <sup>c</sup>	-4.2 <sup>c</sup>	-4.6 <sup>c</sup>	-3.2 <sup>c</sup>
Stomach	-1.0	-2.0	0.5	-2.3 <sup>c</sup>	-2.5 <sup>c</sup>	-1.9 <sup>c</sup>
Small intestine	3.3 <sup>c</sup>	1.9	5.6 <sup>c</sup>	-1.2	-1.2	-1.1
Colon & Rectum:	-0.2	-0.4	0.1	-0.6 <sup>c</sup>	-0.6 <sup>c</sup>	-0.7 <sup>c</sup>
Colon	-0.1	-0.3	0.1	-0.5 <sup>c</sup>	-0.6	-0.5 <sup>c</sup>
Rectum	-0.4	-0.7	0.0	-1.3 <sup>c</sup>	-0.8	-2.0 <sup>c</sup>
Anus, anal canal & anorectum	0.1	-0.1	0.2	-0.9	-1.4	-1.7
Liver & Intrahep:	3.5 <sup>c</sup>	4.3 <sup>c</sup>	2.3	1.4 <sup>c</sup>	1.6	0.8
Liver	3.7 <sup>c</sup>	4.4 <sup>c</sup>	2.6	1.0	1.4	-0.3
Intrahep bile duct	0.8	3.6	-0.3	4.8 <sup>c</sup>	3.1	6.5 <sup>c</sup>
Gallbladder	-0.7	-3.0	0.2	-0.8	0.2	-1.1
Other biliary	-1.2	-1.2	-1.7	-2.8 <sup>c</sup>	-0.8	-3.7 <sup>c</sup>
Pancreas	-1.8 <sup>c</sup>	-1.0 <sup>c</sup>	-2.7 <sup>c</sup>	-0.9 <sup>c</sup>	-1.4 <sup>c</sup>	-0.7 <sup>c</sup>
Retroperitoneum	-3.5	3.5	-5.0	-4.0	4.0	-8.9
Peritoneum, omentum & mesentery	7.7	-	7.4	6.9 <sup>c</sup>	4.2	7.6 <sup>c</sup>
Other digestive system	3.0	-0.4	6.5	7.0	7.3	7.5
Respiratory System:	-1.5 <sup>c</sup>	-2.6 <sup>c</sup>	0.6	-1.4 <sup>c</sup>	-2.4 <sup>c</sup>	0.6 <sup>c</sup>
Nose, nasal cavity & middle ear	-2.6	-2.7	-2.6	-5.3 <sup>c</sup>	-7.4 <sup>c</sup>	-4.0
Larynx	-3.3 <sup>c</sup>	-3.4 <sup>c</sup>	-2.3	-2.5 <sup>c</sup>	-2.5 <sup>c</sup>	-2.5 <sup>c</sup>
Lung & bronchus	-1.4 <sup>c</sup>	-2.5 <sup>c</sup>	0.8	-1.3 <sup>c</sup>	-2.4 <sup>c</sup>	0.8 <sup>c</sup>
Pleura	-3.5	-4.5	0.8	-5.1 <sup>c</sup>	-6.5 <sup>c</sup>	-0.6
Trachea & other respiratory organs	8.0	10.8	9.5	-8.5 <sup>c</sup>	-5.2	-12.6 <sup>c</sup>
Bones & joints	-3.0	-2.2	-5.3	-4.0	-3.6	-5.5
Soft tissue (incl heart)	1.3	1.4	1.8	-2.4	0.6	-4.0 <sup>c</sup>
Skin (ex basal & squam):	-6.4 <sup>c</sup>	-8.0 <sup>c</sup>	0.9	-3.8 <sup>c</sup>	-3.8 <sup>c</sup>	-3.4
Melanoma of the skin	1.8	6.0	-1.1	0.1	1.3	-0.5
Other non-epithelial skin	-8.5 <sup>c</sup>	-10.9 <sup>c</sup>	2.2	-6.3 <sup>c</sup>	-5.8 <sup>c</sup>	-7.2 <sup>c</sup>
Breast	0.2	6.9	0.2	-1.0 <sup>c</sup>	1.3	-1.1 <sup>c</sup>
Breast (in situ)	7.3 <sup>c</sup>	-	7.3 <sup>c</sup>	-	-	-

- <sup>a</sup> The APC is the Annual Percent Change over the time interval.  
SEER 12 areas. Rates are per 100,000 and are age-adjusted to the 2000 U. S. standard population by 5-year age groups.
- <sup>b</sup> NCHS public use data file. Rates are per 100,000 and are age-adjusted to the 2000 U. S. standard population by 5-year age groups.
- <sup>c</sup> The APC is significantly different from zero (p<.05).
- Statistic could not be calculated.

Table I-10 - continued  
SEER INCIDENCE AND U.S. MORTALITY TRENDS BY PRIMARY CANCER SITE AND SEX  
Blacks, 1992-2000

Site	Incidence <sup>a</sup>			US Mortality <sup>b</sup>		
	Total APC	Males APC	Females APC	Total APC	Males APC	Females APC
Female Genital System:	-1.1	-	-1.0	-1.9 <sup>c</sup>	-	-1.9 <sup>c</sup>
Cervix uteri	-2.7 <sup>c</sup>	-	-2.7 <sup>c</sup>	-4.8 <sup>c</sup>	-	-4.8 <sup>c</sup>
Corpus uteri	0.3	-	0.4	-1.0	-	-1.0
Uterus, NOS	-2.7	-	-3.2	0.7	-	0.8
Ovary	-0.7	-	-0.7	-1.3 <sup>c</sup>	-	-1.2 <sup>c</sup>
Vagina	-2.2	-	-2.1	-2.6	-	-2.7
Vulva	-2.0	-	-1.8	-3.8	-	-3.9
Other female genital system	-4.3	-	-3.3	3.8	-	3.6
Male Genital System:	-1.7 <sup>c</sup>	-2.2 <sup>c</sup>	-	-2.3 <sup>c</sup>	-2.1 <sup>c</sup>	-
Prostate	-1.8 <sup>c</sup>	-2.3 <sup>c</sup>	-	-2.3 <sup>c</sup>	-2.1 <sup>c</sup>	-
Testis	7.5 <sup>c</sup>	7.9 <sup>c</sup>	-	2.5	2.5	-
Penis	-2.0	-1.1	-	-6.2 <sup>c</sup>	-6.7 <sup>c</sup>	-
Other male genital system	-	-	-	3.6	6.1	-
Urinary System:	0.9	0.5	1.8	-0.7 <sup>c</sup>	-0.8 <sup>c</sup>	-0.7
Urinary bladder	0.3	0.2	0.8	-1.5 <sup>c</sup>	-1.8 <sup>c</sup>	-1.1
Kidney & renal pelvis	1.8	1.0	3.1	0.2	0.4	-0.2
Ureter	-1.3	2.2	0.7	-5.8 <sup>c</sup>	-10.3 <sup>c</sup>	-2.1
Other urinary system	-3.6 <sup>c</sup>	-2.0	-4.2	-3.8	-4.3	-3.2
Eye & Orbit	-1.9	-0.5	-2.1	5.7	10.4	4.4
Brain & Nervous System: <sup>d</sup>	0.0	1.2	-0.9	-0.3	-0.6	-0.3
Brain	0.1	1.4	-1.2	-	-	-
Cranial nerves & other nervous system	-0.6	0.5	0.0	-	-	-
Endocrine System:	2.4 <sup>c</sup>	-1.1	3.6 <sup>c</sup>	0.8	0.3	1.2
Thyroid	3.1 <sup>c</sup>	-0.9	4.3 <sup>c</sup>	2.2	3.3	1.7
Other endocrine & thymus	-1.4	-2.2	-1.0	-0.9	-2.0	0.4
Lymphoma:	0.2	-1.1	2.2	-0.5	-0.6	-0.3
Hodgkin lymphoma	-0.7	0.9	-2.5	-5.0 <sup>c</sup>	-5.8 <sup>c</sup>	-4.2 <sup>c</sup>
Non-Hodgkin lymphoma	0.4	-1.4	3.2 <sup>c</sup>	-0.1	-0.1	0.0
Myeloma	-1.8	-2.1	-1.6	-0.2	-0.8	0.3
Leukemia:	-1.0	-0.9	-0.9	-1.0 <sup>c</sup>	-0.9	-0.8
Lymphocytic:	-2.6	-2.4	-2.5	-2.1 <sup>c</sup>	-2.4 <sup>c</sup>	-1.2
Acute lymphocytic	-0.6	0.1	-1.8	-2.9	-2.5	-3.4
Chronic lymphocytic	-3.4	-2.7	-3.5	-1.9	-2.6 <sup>c</sup>	-0.4
Other lymphocytic	0.2	-3.7	-	-1.5	-0.3	-2.9
Myeloid & Monocytic:	1.7	2.4	1.0	0.1	0.4	-0.2
Acute myeloid	4.1 <sup>c</sup>	6.5 <sup>c</sup>	1.8	2.0 <sup>c</sup>	2.1 <sup>c</sup>	1.8 <sup>c</sup>
Chronic myeloid	-3.2	-4.1	-2.3	-4.2 <sup>c</sup>	-3.8	-4.7 <sup>c</sup>
Acute monocytic	4.8	8.2	-	-8.7	-	-4.6
Other myeloid & monocytic	5.6	-	11.9 <sup>c</sup>	7.6 <sup>c</sup>	9.6	4.3
Other:	-8.1 <sup>c</sup>	-11.2	-5.6	-1.5 <sup>c</sup>	-0.9	-1.5
Other acute	-7.9 <sup>c</sup>	-9.2	-10.2	-3.2 <sup>c</sup>	-3.2 <sup>c</sup>	-2.6
Aleukemic, subleuk & NOS	-8.0 <sup>c</sup>	-13.3	-0.5	-0.2	0.7	-0.6
Ill-defined & unspecified	-3.9 <sup>c</sup>	-3.1 <sup>c</sup>	-4.5 <sup>c</sup>	-0.5	-0.4	-0.4

- <sup>a</sup> The APC is the Annual Percent Change over the time interval.  
SEER 12 areas. Rates are per 100,000 and are age-adjusted to the 2000 U. S. standard population by 5-year age groups.
- <sup>b</sup> NCHS public use data file. Rates are per 100,000 and are age-adjusted to the 2000 U. S. standard population by 5-year age groups.
- <sup>c</sup> The APC is significantly different from zero (p<.05).
- <sup>d</sup> Due to coding changes, Brain & Nervous System mortality are no longer shown separately.
- Statistic could not be calculated.

Table I-11

## AGE DISTRIBUTION (%) OF INCIDENCE CASES BY SITE, 1996-2000

All Races, Both Sexes

Site	<20	20-34	35-44	45-54	55-64	65-74	75-84	85+	All Ages	Cases
All Sites	1.1	3.0	6.4	13.0	19.3	27.5	22.4	7.3	100.0%	805,904
Oral cavity & Pharynx	0.6	3.0	7.9	19.1	22.2	24.8	17.1	5.4	100.0%	18,753
Esophagus	0.0	0.5	2.8	11.8	22.1	31.5	23.9	7.3	100.0%	7,657
Stomach	0.1	1.7	4.9	9.6	16.0	27.2	27.9	12.7	100.0%	15,358
Colon & Rectum	0.1	1.0	3.4	9.4	16.7	27.7	29.4	12.5	100.0%	90,922
Males	0.1	1.0	3.6	10.3	18.9	30.0	27.6	8.6	100.0%	45,710
Females	0.0	0.9	3.1	8.6	14.4	25.3	31.2	16.4	100.0%	45,212
Colon	0.1	0.8	2.9	8.0	15.3	27.7	31.3	14.0	100.0%	65,493
Rectum	0.1	1.3	4.6	13.0	20.2	27.8	24.3	8.8	100.0%	25,429
Liver & Intrahep	1.4	1.3	4.6	15.9	20.0	27.2	22.6	7.1	100.0%	10,047
Pancreas	0.1	0.5	2.7	9.3	16.9	28.7	29.5	12.3	100.0%	18,553
Larynx	0.0	0.5	4.1	14.5	26.9	32.7	17.5	3.8	100.0%	6,640
Lung & Bronchus	0.0	0.3	2.2	8.8	20.6	34.8	27.0	6.3	100.0%	105,204
Males	0.0	0.3	2.1	8.8	21.3	35.4	26.4	5.7	100.0%	58,315
Females	0.0	0.3	2.3	8.8	19.7	34.0	27.7	7.1	100.0%	46,889
Melanoma of the skin	0.8	9.7	15.8	19.5	16.8	18.5	14.1	4.8	100.0%	29,267
Breast(females)	0.0	2.0	10.9	21.9	20.9	21.7	17.0	5.5	100.0%	126,280
Breast(females, <i>in situ</i> )	0.0	1.0	12.0	28.8	23.0	20.9	12.5	2.0	100.0%	26,458
Cervix uteri	0.3	15.9	26.8	22.6	13.7	11.0	7.0	2.7	100.0%	9,177
Corpus & Uterus, NOS	0.0	1.5	6.2	17.7	24.9	25.7	18.6	5.4	100.0%	22,845
Ovary	1.3	6.4	10.8	19.5	18.9	21.0	16.6	5.7	100.0%	15,792
Prostate	0.0	0.0	0.4	7.1	24.6	39.3	23.6	4.9	100.0%	123,458
Testis	5.4	47.2	31.5	11.7	2.6	0.9	0.7	0.0	100.0%	5,174
Urinary bladder	0.1	0.7	2.6	8.2	16.4	30.5	30.9	10.8	100.0%	34,052
Kidney & Renal pelvis	2.1	1.4	6.3	15.4	21.9	26.9	20.2	5.8	100.0%	18,929
Brain & Other nervous	13.3	9.9	11.5	14.4	15.1	18.1	14.4	3.4	100.0%	11,432
Thyroid	2.4	21.3	23.5	21.4	13.5	10.2	6.2	1.5	100.0%	12,605
Hodgkin lymphoma	12.8	33.9	18.0	11.9	8.3	7.7	5.8	1.6	100.0%	5,069
Non-Hodgkin lymphoma	1.7	5.4	9.4	13.5	16.4	23.7	22.5	7.4	100.0%	32,951
Myeloma	0.0	0.6	3.3	11.1	17.8	29.2	28.8	9.1	100.0%	9,406
Leukemia	11.6	5.2	6.1	9.7	13.3	21.6	22.7	9.9	100.0%	20,940
Acute lymphocytic	64.6	9.0	6.2	5.6	4.4	5.1	3.7	1.3	100.0%	2,886
Chronic lymphocytic	0.0	0.3	2.4	9.8	17.8	28.8	28.4	12.6	100.0%	5,876
Acute myeloid	6.3	7.3	7.3	9.9	13.3	23.2	24.1	8.6	100.0%	6,427
Chronic myeloid	1.9	8.7	10.4	12.3	13.4	21.8	21.7	9.9	100.0%	2,890
All other leukemia	3.4	3.0	6.7	10.4	12.6	20.0	27.8	16.2	100.0%	2,861

Source: SEER 12 areas.

Table I-12  
MEDIAN AGE OF CANCER PATIENTS AT DIAGNOSIS<sup>a</sup>, 1996-2000  
 By Primary Cancer Site, Race and Sex

Site	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Sites	67.0	68.0	65.0	67.0	68.0	66.0	64.0	65.0	62.0
Oral Cavity & Pharynx:	63.0	62.0	65.0	64.0	63.0	67.0	55.5	56.0	55.0
Lip	67.0	64.0	72.0	67.5	64.0	75.0	66.0	-	66.0
Tongue	62.0	59.0	65.0	62.0	60.5	66.0	55.0	50.0	63.0
Salivary gland	62.0	64.0	57.5	64.0	64.5	61.0	38.0	34.0	60.0
Floor of mouth	64.0	61.0	66.0	65.0	63.5	66.0	57.0	53.0	64.0
Gum & other oral cavity	69.0	69.0	72.0	70.0	69.0	73.5	54.0	56.0	48.5
Nasopharynx	53.0	55.0	51.0	56.0	56.0	58.0	-	-	-
Tonsil	59.0	57.0	64.0	59.0	57.0	64.0	54.0	54.0	54.0
Oropharynx	64.0	64.0	62.0	65.0	64.5	67.0	49.0	50.5	48.0
Hypopharynx	64.0	65.0	60.0	64.5	64.5	67.0	64.0	67.5	53.0
Other oral cavity & pharynx	66.5	66.0	67.0	67.0	66.5	67.0	62.0	62.0	59.5
Digestive System:	71.0	70.0	74.0	72.0	70.0	75.0	68.0	66.0	70.0
Esophagus	70.0	68.0	73.0	71.0	70.0	75.0	62.0	62.0	62.0
Stomach	72.0	71.0	74.0	73.0	71.0	76.0	70.5	71.0	69.0
Small intestine	69.0	63.0	69.0	69.5	62.5	70.0	61.5	62.0	61.0
Colon & Rectum:	72.0	70.0	74.0	73.0	71.0	75.0	69.0	66.0	70.0
Colon	73.0	71.0	74.0	73.0	72.0	75.0	69.0	66.0	70.0
Rectum	69.0	68.0	71.0	70.0	69.0	72.0	68.0	67.0	72.0
Anus, anal canal & anorectum	62.0	61.0	63.5	62.0	61.0	63.0	56.0	62.0	44.0
Liver & Intrahep:	67.0	65.0	72.0	68.0	65.0	72.0	65.0	63.5	74.0
Liver	67.0	65.0	70.0	67.0	65.0	71.5	65.0	63.0	75.5
Intrahep bile duct	71.0	66.0	76.0	70.5	64.5	76.0	61.0	73.0	58.0
Gallbladder	75.0	76.0	73.0	75.0	76.0	75.0	69.5	72.0	56.0
Other biliary	73.5	74.0	72.5	75.0	75.0	74.0	64.0	62.5	64.0
Pancreas	73.0	70.5	75.0	73.0	71.0	76.0	69.0	66.0	72.0
Retroperitoneum	65.0	66.0	55.0	63.0	68.0	54.0	46.0	-	46.0
Peritoneum, omentum & mesentery	65.0	68.0	64.0	65.5	69.0	64.0	66.0	-	66.0
Other digestive system	70.0	67.0	75.0	69.0	66.0	75.0	66.0	67.0	65.0
Respiratory System:	70.0	69.0	70.0	70.0	70.0	71.0	66.0	66.0	66.0
Nose, nasal cavity & middle ear	65.0	63.0	71.0	66.0	63.0	75.0	44.0	44.0	-
Larynx	66.0	66.0	65.0	66.0	66.5	66.0	61.0	62.5	55.0
Lung & bronchus	70.0	70.0	70.0	70.0	70.0	71.0	66.0	66.0	67.0
Pleura	72.0	72.0	74.0	72.5	72.0	81.5	58.5	64.5	58.5
Trachea & other respiratory organs	59.0	48.5	70.5	63.0	48.5	71.0	62.5	55.0	70.0
Bones & joints	35.0	35.0	36.5	36.0	35.0	38.0	37.5	41.0	27.0
Soft tissue (incl heart)	57.0	56.0	57.0	58.0	59.0	57.0	47.5	42.0	59.0
Skin (ex basal & squam):	57.0	58.0	53.0	57.0	59.0	54.0	39.5	39.0	47.0
Melanoma of the skin	57.0	60.0	53.0	58.0	61.0	53.0	74.5	74.5	66.5
Other non-epithelial skin	49.0	45.0	61.0	52.0	49.0	64.0	38.0	38.0	38.0
Breast	62.0	67.0	62.0	63.0	68.5	63.0	56.0	62.0	56.0
Breast (in situ) <sup>b</sup>	-	-	57.0	-	-	58.0	-	-	54.0

<sup>a</sup> SEER 12 areas.

<sup>b</sup> Females only.

- Statistic could not be calculated.

Table I-12 - continued  
MEDIAN AGE OF CANCER PATIENTS AT DIAGNOSIS<sup>a</sup>, 1996-2000  
 By Primary Cancer Site, Race and Sex

Site	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	61.0	-	61.0	61.0	-	61.0	60.0	-	60.0
Cervix uteri	47.0	-	47.0	46.0	-	46.0	51.0	-	51.0
Corpus uteri	65.0	-	65.0	66.0	-	66.0	64.0	-	64.0
Uterus, NOS	79.0	-	79.0	75.0	-	75.0	85.5	-	85.5
Ovary	59.0	-	59.0	59.0	-	59.0	63.5	-	63.5
Vagina	69.0	-	69.0	70.0	-	70.0	42.0	-	42.0
Vulva	67.5	-	67.5	68.0	-	68.0	58.0	-	58.0
Other female genital system	62.5	-	62.5	64.0	-	64.0	47.0	-	47.0
Male Genital System:	68.0	68.0	-	69.0	69.0	-	66.0	66.0	-
Prostate	69.0	69.0	-	69.0	69.0	-	66.0	66.0	-
Testis	34.0	34.0	-	34.0	34.0	-	43.0	43.0	-
Penis	69.0	69.0	-	69.0	69.0	-	86.0	86.0	-
Other male genital system	68.0	68.0	-	71.0	71.0	-	35.0	35.0	-
Urinary System:	70.0	70.0	70.0	71.0	71.0	71.0	66.0	67.0	65.0
Urinary bladder	72.0	72.0	72.0	72.0	72.0	73.0	72.0	72.0	72.0
Kidney & renal pelvis	66.0	64.0	66.5	66.0	65.0	68.0	60.0	60.5	59.0
Ureter	72.0	72.0	73.0	74.0	73.0	74.0	56.0	65.0	52.0
Other urinary system	71.0	72.0	69.5	72.5	73.0	71.0	49.5	48.0	64.0
Eye & Orbit	62.5	65.0	60.5	65.0	65.0	62.0	61.5	72.0	51.0
Brain & Nervous System:	53.0	52.5	54.0	54.0	54.0	54.0	54.0	52.0	63.0
Brain	54.0	54.0	54.0	54.0	56.0	54.0	54.0	52.0	63.0
Cranial nerves & other nervous system	46.0	33.0	57.5	44.5	29.0	62.0	57.0	-	57.0
Endocrine System:	46.0	50.0	45.0	45.0	48.0	45.0	47.0	55.0	46.5
Thyroid	46.0	51.0	45.0	45.0	50.0	45.0	47.0	52.0	46.0
Other endocrine & thymus	46.5	44.5	49.5	42.5	42.0	50.0	60.0	71.0	49.0
Lymphomas:	64.0	60.0	67.0	65.0	62.0	69.0	48.0	48.0	46.5
Hodgkin lymphoma	35.0	38.0	32.0	36.0	38.0	33.0	29.0	35.0	28.0
Non-Hodgkin lymphoma	66.5	64.0	69.0	67.5	65.0	70.0	51.0	51.0	51.0
Myeloma	71.0	69.5	72.0	71.0	70.0	73.0	66.0	64.0	69.0
Leukemia:	66.0	65.0	67.0	67.0	67.0	68.0	64.0	53.0	72.0
Lymphocytic:	66.0	64.5	67.0	67.0	65.0	67.0	66.0	66.5	64.0
Acute lymphocytic	11.0	11.0	11.0	12.0	11.0	12.0	11.0	17.0	9.0
Chronic lymphocytic	72.0	71.0	72.0	72.0	71.0	73.0	69.0	69.0	69.5
Other lymphocytic	67.0	67.0	63.0	68.0	68.5	63.0	66.0	66.0	-
Myeloid & Monocytic:	65.0	63.0	66.0	66.5	66.0	67.0	55.0	43.0	72.0
Acute myeloid	65.0	64.0	66.0	66.0	66.0	66.0	59.0	50.0	72.0
Chronic myeloid	66.0	63.0	68.0	67.0	66.0	70.5	37.5	35.0	68.0
Acute monocytic	47.0	42.0	54.0	52.5	53.5	47.5	57.5	30.0	85.0
Other myeloid & monocytic	77.0	82.0	75.0	76.0	82.0	75.0	84.0	84.0	64.5
Other:	79.0	79.0	79.0	80.0	80.0	79.0	75.5	73.0	77.5
Other acute	77.0	76.0	78.0	79.0	80.0	79.0	70.5	68.0	73.0
Aleukemic, subleuk & NOS	80.0	80.0	80.0	82.0	84.5	79.5	80.0	78.0	82.0
Ill-defined & unspecified	74.0	71.0	76.0	75.0	73.0	76.0	65.0	61.0	73.0

<sup>a</sup> SEER 12 areas.  
 - Statistic could not be calculated.

Table I-13

## AGE DISTRIBUTION (%) OF DEATHS BY SITE, 1996-2000

All Races, Both Sexes

Site	<20	20-34	35-44	45-54	55-64	65-74	75-84	85+	All Ages	Cases
All Sites	0.4	1.0	3.1	8.5	16.1	28.5	29.3	13.2	100.0%	2,723,650
Oral cavity & Pharynx	0.2	0.9	4.0	13.4	21.7	27.3	22.0	10.5	100.0%	38,689
Esophagus	0.0	0.3	2.3	10.7	21.3	31.6	25.1	8.8	100.0%	58,421
Stomach	0.0	1.1	3.8	8.3	14.2	25.6	30.5	16.6	100.0%	64,709
Colon & Rectum	0.0	0.6	2.2	6.8	13.7	25.8	31.4	19.4	100.0%	285,077
Males	0.0	0.6	2.4	7.7	16.1	29.3	30.7	13.2	100.0%	140,884
Females	0.0	0.5	2.1	5.9	11.3	22.5	32.2	25.5	100.0%	144,193
Colon	0.0	0.5	2.1	6.4	13.3	25.7	32.0	20.0	100.0%	244,108
Rectum	0.1	0.8	3.2	8.9	16.4	26.8	27.9	16.0	100.0%	40,969
Liver & Intrahep	0.5	0.9	3.5	11.4	16.8	28.7	27.6	10.6	100.0%	61,200
Pancreas	0.0	0.2	2.0	7.6	15.8	28.8	31.5	14.1	100.0%	141,678
Larynx	0.0	0.1	2.0	10.9	24.0	32.5	23.7	6.8	100.0%	19,270
Lung & Bronchus	0.0	0.2	1.8	7.6	19.3	35.0	28.5	7.7	100.0%	767,060
Males	0.0	0.1	1.7	7.7	20.0	35.9	27.9	6.7	100.0%	454,037
Females	0.0	0.2	1.9	7.4	18.2	33.7	29.5	9.1	100.0%	313,023
Melanoma of the skin	0.1	3.5	9.1	15.3	17.0	23.2	22.0	9.8	100.0%	36,583
Breast(females)	0.0	1.2	7.0	15.1	17.7	22.5	22.7	13.7	100.0%	209,785
Cervix uteri	0.0	6.3	17.3	21.3	17.3	16.8	13.6	7.5	100.0%	21,783
Corpus & Uterus, NOS	0.0	0.4	2.0	6.8	15.6	28.6	30.5	16.0	100.0%	31,972
Ovary	0.1	0.9	3.5	11.0	17.4	27.3	28.2	11.7	100.0%	67,745
Prostate	0.0	0.0	0.1	1.2	6.3	23.9	42.3	26.3	100.0%	162,020
Testis	2.2	35.4	29.6	14.0	7.3	5.2	4.6	1.8	100.0%	1,747
Urinary bladder	0.0	0.1	0.9	3.7	9.9	24.9	36.9	23.7	100.0%	58,702
Kidney & Renal pelvis	0.5	0.6	3.0	10.5	18.8	28.3	27.0	11.3	100.0%	56,725
Brain & Other nervous	4.4	4.4	8.5	14.5	18.9	25.1	19.2	5.1	100.0%	62,935
Thyroid	0.2	1.0	2.7	7.6	15.0	26.0	31.5	16.1	100.0%	6,155
Hodgkin lymphoma	2.4	17.1	13.6	12.0	11.8	18.4	18.1	6.7	100.0%	6,852
Non-Hodgkin lymphoma	0.5	2.2	4.1	7.9	13.8	25.9	32.0	13.6	100.0%	115,376
Myeloma	0.0	0.2	1.5	6.3	15.0	30.0	33.7	13.4	100.0%	52,011
Leukemia	3.4	3.6	4.1	6.7	11.7	24.4	30.5	15.7	100.0%	103,915
Acute lymphocytic	22.8	15.5	9.0	9.8	10.6	13.5	13.2	5.7	100.0%	6,974
Chronic lymphocytic	0.0	0.1	0.6	3.1	9.7	25.6	36.2	24.8	100.0%	21,474
Acute myeloid	3.1	4.0	5.0	8.4	13.7	27.0	28.7	10.0	100.0%	33,810
Chronic myeloid	1.3	5.2	7.7	11.2	14.4	23.2	25.2	11.6	100.0%	10,526
All other leukemia	2.5	2.4	3.0	5.2	10.2	23.7	34.0	19.1	100.0%	31,131

Source: NCHS public use data file.

Table I-14  
MEDIAN AGE OF CANCER PATIENTS AT DEATH<sup>a</sup>, 1996-2000  
 By Primary Cancer Site, Race and Sex

Site	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Sites	72.0	72.0	73.0	73.0	72.0	73.0	69.0	69.0	69.0
Oral Cavity & Pharynx:	68.0	66.0	72.0	69.0	67.0	73.5	60.0	59.0	64.0
Lip	74.0	72.0	81.0	74.0	72.0	82.0	71.5	-	71.5
Tongue	67.0	64.0	71.0	68.0	66.0	73.0	59.0	59.0	61.0
Salivary gland	73.0	73.0	74.0	74.0	74.0	74.0	61.0	57.0	66.5
Floor of mouth	66.0	65.0	69.5	67.0	66.5	70.0	58.0	56.5	58.0
Gum & other	71.0	67.0	78.0	73.0	68.0	78.0	63.0	59.0	76.0
oral cavity									
Nasopharynx	64.0	60.0	67.5	66.0	64.0	69.0	59.0	52.0	62.0
Tonsil	62.0	62.0	67.0	63.0	62.0	69.0	59.0	59.0	57.0
Oropharynx	67.0	65.0	71.0	69.0	67.0	71.0	59.5	59.0	71.0
Hypopharynx	67.0	66.0	70.0	69.0	69.0	69.0	61.0	58.5	72.0
Other oral cavity & pharynx	68.0	67.0	72.0	70.0	68.0	73.0	61.0	59.0	63.5
Digestive System:	73.0	71.0	76.0	74.0	72.0	77.0	70.0	67.0	72.0
Esophagus	70.0	68.0	74.0	70.0	69.0	75.0	64.0	63.0	67.0
Stomach	73.0	71.0	76.0	74.0	72.0	77.0	71.0	68.0	74.0
Small intestine	73.0	72.0	74.0	74.0	73.0	75.0	64.0	66.0	61.5
Colon & Rectum	75.0	72.0	77.0	75.0	73.0	78.0	71.0	69.0	73.0
Anus, anal canal & anorectum	68.0	63.5	70.0	68.0	65.0	70.0	60.0	52.0	76.0
Liver & Intrahep:	71.0	69.0	74.0	72.0	70.0	75.0	64.0	61.0	69.0
Liver	70.0	68.0	74.0	71.0	70.0	75.0	64.0	61.0	69.0
Intrahep bile duct	73.0	71.0	74.0	73.0	71.0	75.0	69.5	71.0	69.0
Gallbladder	75.0	75.0	75.0	75.0	76.0	75.0	72.0	71.0	72.0
Other biliary	76.0	75.0	78.0	76.0	75.0	78.0	73.5	73.5	73.5
Pancreas	73.0	71.0	75.0	74.0	71.0	76.0	70.0	67.0	72.0
Retroperitoneum	68.0	69.0	64.0	68.0	69.0	64.0	58.0	61.0	53.5
Peritoneum, omentum & mesentery	70.0	68.0	71.0	70.0	67.5	71.0	69.0	71.0	61.5
Other digestive system	78.0	74.0	82.0	78.0	74.0	82.0	76.0	71.5	78.0
Respiratory System:	71.0	71.0	71.0	71.0	71.0	72.0	67.0	67.0	68.0
Nose, nasal cavity & middle ear	67.5	64.0	71.0	69.0	65.0	71.0	64.5	59.5	73.0
Larynx	69.0	68.0	70.0	70.0	69.0	72.0	62.0	62.0	64.0
Lung & bronchus	71.0	71.0	71.0	71.0	71.0	72.0	68.0	67.0	68.0
Pleura	73.0	72.0	73.0	73.0	72.0	73.0	71.5	70.5	73.5
Trachea & other respiratory organs	67.0	64.0	72.5	67.0	64.0	73.0	64.5	65.5	58.5
Bones & joints	61.0	56.0	68.0	62.0	57.0	69.5	39.0	41.0	36.0
Soft tissue (incl heart)	66.0	65.0	67.0	67.0	66.0	69.0	55.0	50.0	57.0
Skin (ex basal & squam):	69.0	68.0	71.0	69.0	68.0	71.0	62.0	58.5	73.0
Melanoma of the skin	67.0	67.0	69.0	67.0	67.0	69.0	71.0	51.5	75.0
Other non-epithelial skin	74.0	72.0	79.0	75.0	74.0	80.0	60.5	59.0	66.0
Breast	69.0	71.0	69.0	70.0	72.0	70.0	61.0	66.5	61.0

<sup>a</sup> NCHS public use data file.  
 - Statistic could not be calculated.



Table I-14 - continued  
MEDIAN AGE OF CANCER PATIENTS AT DEATH<sup>a</sup>, 1996-2000  
 By Primary Cancer Site, Race and Sex

Site	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	71.0	-	71.0	72.0	-	72.0	67.0	-	67.0
Cervix uteri	57.0	-	57.0	58.0	-	58.0	57.0	-	57.0
Corpus uteri	73.0	-	73.0	73.0	-	73.0	70.0	-	70.0
Uterus, NOS	74.0	-	74.0	75.0	-	75.0	71.0	-	71.0
Ovary	71.0	-	71.0	72.0	-	72.0	68.0	-	68.0
Vagina	74.0	-	74.0	75.0	-	75.0	71.0	-	71.0
Vulva	79.5	-	79.5	80.0	-	80.0	73.5	-	73.5
Other female genital system	70.0	-	70.0	70.5	-	70.5	60.0	-	60.0
Male Genital System:	79.0	79.0	-	79.0	79.0	-	77.0	77.0	-
Prostate	79.0	79.0	-	79.0	79.0	-	77.0	77.0	-
Testis	39.0	39.0	-	39.0	39.0	-	39.5	39.5	-
Penis	70.0	70.0	-	70.5	70.5	-	68.0	68.0	-
Other male genital system	71.5	71.5	-	73.0	73.0	-	61.0	61.0	-
Urinary System:	74.0	73.0	77.0	75.0	73.0	77.0	71.0	69.0	73.0
Urinary bladder	77.0	76.0	80.0	78.0	76.0	80.0	76.0	75.0	77.0
Kidney & renal pelvis	71.0	69.0	73.0	71.0	69.0	74.0	67.0	65.0	70.0
Ureter	77.0	75.0	80.0	77.0	75.0	79.0	80.5	79.0	86.0
Other urinary system	76.0	75.0	76.0	77.0	76.0	78.0	69.0	56.0	73.5
Eye & Orbit	74.0	74.0	73.0	74.0	74.5	74.0	36.0	35.0	37.0
Brain & Nervous System:	64.0	62.0	67.0	65.0	63.0	67.0	58.0	56.0	62.0
Endocrine System:	69.0	66.0	72.0	69.0	67.0	72.0	64.5	58.0	69.0
Thyroid	73.0	69.0	76.0	74.0	70.0	76.0	70.0	66.5	74.0
Other endocrine & thymus	57.0	57.0	59.0	59.0	58.5	59.0	45.0	36.0	53.0
Lymphoma:	73.0	70.0	75.0	73.0	71.0	76.0	63.0	59.0	67.0
Hodgkin lymphoma	58.0	56.0	59.0	59.0	58.0	61.0	39.0	40.0	38.0
Non-Hodgkin lymphoma	73.0	71.0	76.0	74.0	71.0	76.0	64.0	60.0	68.0
Myeloma	74.0	73.0	75.0	75.0	74.0	75.5	70.0	69.0	71.0
Leukemia:	73.0	72.0	75.0	74.0	73.0	76.0	67.0	66.0	69.0
Lymphocytic:	75.0	73.0	78.0	75.0	73.0	78.0	71.0	68.0	74.0
Acute lymphocytic	50.0	48.0	53.0	52.0	51.0	54.0	37.0	22.0	48.0
Chronic lymphocytic	77.0	75.0	81.0	78.0	76.0	81.0	75.0	73.0	78.0
Other lymphocytic	77.0	76.0	79.0	77.0	77.0	79.0	73.0	66.0	82.0
Myeloid & Monocytic:	71.0	71.0	72.0	72.0	71.0	72.0	62.0	61.0	63.0
Acute myeloid	71.0	71.0	71.0	72.0	71.0	72.0	64.0	65.0	64.0
Chronic myeloid	69.0	68.0	71.0	71.0	70.0	72.0	58.0	56.0	58.5
Acute monocytic	71.0	72.0	70.0	71.0	72.0	70.5	67.0	69.0	48.0
Other myeloid & monocytic	76.0	75.0	78.0	76.0	75.0	78.0	81.0	79.0	84.0
Other:	76.0	75.0	78.0	76.0	75.0	78.0	73.0	73.0	73.0
Other acute	75.0	74.0	76.0	75.0	74.0	77.0	72.0	72.0	70.0
Aleukemic, subleuk & NOS	77.0	75.0	79.0	77.0	76.0	80.0	73.0	74.0	73.0
Ill-defined & unspecified	73.0	71.0	75.0	74.0	72.0	76.0	69.0	67.0	71.0

<sup>a</sup> NCHS public use data file.  
 - Statistic could not be calculated.

Table I-15

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site, Race and Sex

12 SEER Areas, 1998-2000

Site	All Races		Whites		Blacks	
	Males	Females	Males	Females	Males	Females

Data will be available shortly.

Note: Invasive cancer only unless specified otherwise.

Table I-16

Lifetime Risk (Percent) of Dying from Cancer by Site, Race and Sex

Total U.S., 1998-2000

Site	All Races		Whites		Blacks	
	Males	Females	Males	Females	Males	Females

Data will be available shortly.

# Surveillance, Epidemiology, and End Results Program, 2003

## National Cancer Institute

### U.S.A




Figure I-1

<http://seer.cancer.gov>

# Leading Causes of Death in US Percent of All Causes of Death 1975 vs 2000





Figure I-2

Source: NCHS public use data file.

# US Death Rates 1975-2000


Figure I-3



Source: NCHS public use data file. Rates are per 100,000 and age-adjusted to the 2000 US standard population by 5-year age groups.

# Trends in SEER Incidence & US Death Rates by Primary Cancer Site 1992-2000


Figure I-4



The APC is the Annual Percent Change over the time interval.  
SEER 12 areas and NCHS public use data file. Rates are per 100,000 and age-adjusted to the 2000 US standard population by 5-year age groups.  
\* The APC is significantly different from zero ( $p < .05$ ).

# Trends in SEER Incidence Rates by Primary Cancer Site 1992-2000

Figure I-5




The APC is the Annual Percent Change over the time interval.  
SEER 12 areas and NCHS public use data file. Rates are per 100,000 and age-adjusted to the 2000 US standard population by 5-year age groups.  
\* The APC is significantly different from zero ( $p < .05$ ).



# Trends in US Death Rates by Primary Cancer Site 1992-2000

Figure I-6




The APC is the Annual Percent Change over the time interval.

NCHS public use data file. Rates are per 100,000 and age-adjusted to the 2000 US standard population by 5-year age groups.

\* The APC is significantly different from zero ( $p < .05$ ).


# Trends in SEER Incidence Rates by Primary Cancer Site 1992-2000



The APC is the Annual Percent Change over the time interval.  
SEER 12 areas. Rates are per 100,000 and age-adjusted to the 2000 US standard population by 5-year age groups.  
\* The APC is significantly different from zero ( $p < .05$ ).


Figure I-10

# Trends in US Death Rates, 1992-2000 by Primary Cancer Site All Ages, by Race



The APC is the Annual Percent Change over the time interval.  
Source: NCHS public use data file.


# SEER Incidence\* and US Death Rates, 1996-2000 5-Year Relative Survival Rates, 1992-1999 All Cancer Combined, by Race and Sex



\* Incidence rates are from the SEER 12 areas and are age-adjusted to the 2000 US standard population by 5-year age groups.  
 # Death rates are from the NCHS public use data file and are age-adjusted to the 2000 US standard population by 5-year age groups.  
 ^ Survival rates are from the SEER 9 areas. Relative survival rates are expressed as percents.

# Trends in US Death Rates by Primary Cancer Site 1992-2000

Figure I-8




The APC is the Annual Percent Change over the time interval.

NCHS public use data file. Rates are per 100,000 and age-adjusted to the 2000 US standard population by 5-year age groups.

\* The APC is significantly different from zero ( $p < .05$ ).

Figure I-11


# 5-Year Relative Survival Rates SEER Program, 1992-1999 Both Sexes, by Race



Source: SEER 9 areas.

Figure I-12

# SEER Cancer Incidence and US Death Rates, 1996-2000 By Cancer Site and Race




Source: SEER 12 areas and NCHS public use data file.

^^ Hispanic is not mutually exclusive from Whites, Blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics excludes Detroit and Hawaii. Mortality data for Hispanics excludes cases from Connecticut, Oklahoma, New York, and New Hampshire.

Rates are per 100,000 and age-adjusted to the 2000 U.S. standard population by 5-year age groups.

# SEER Incidence 1992-2000

## Males by Race/Ethnicity




Source: SEER 12 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, and Alaska). Incidence data for Hispanics does not include cases from Detroit and Hawaii. Regression lines are calculated using the Joinpoint Regression Program. ^^ Hispanic is not mutually exclusive from Whites, Blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Figure I-13




# SEER Incidence 1992-2000 Females by Race/Ethnicity



Source: SEER 12 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, and Alaska). Incidence data for Hispanics does not include cases from Detroit and Hawaii. Regression lines are calculated using the Joinpoint Regression Program. ^^^ Hispanic is not mutually exclusive from Whites, Blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Figure I-14


# US Mortality 1992-2000 Males by Race/Ethnicity



Source: NCHS public use data file. Mortality data for Hispanics does not include cases from Connecticut, Oklahoma, New York, and New Hampshire. Regression lines are calculated using the Joinpoint Regression Program. Hispanic is not mutually exclusive from Whites, Blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Figure I-15


# US Mortality 1992-2000 Females by Race/Ethnicity



Source: NCHS public use data file. Mortality data for Hispanics does not include cases from Connecticut, Oklahoma, New York, and New Hampshire. Regression lines are calculated using the Joinpoint Regression Program.   
 ~~~ Hispanic is not mutually exclusive from Whites, Blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Figure I-17


# Incidence Percent Change, 1992-2000 Numbers (burden) vs Rates (risk) All Ages



US Incidence estimates based on SEER age-specific rates applied to US population.

Figure I-18


# Mortality Percent Change, 1992-2000 Numbers (burden) vs Rates (risk) All Ages




US Mortality estimates based on US age-specific rates applied to US population.

Figure I-19

# Average Years of Life Lost Per Person Dying of Cancer All Races, Both Sexes, 2000




# Person-Years of Life Lost Due to Cancer, All Races Both Sexes, 2000




Estimates produced using 2000 Life Tables

# Person-Years of Life Lost Due to Major Causes of Death in US All Races, Both Sexes, 2000




# Average Years of Life Lost Per Person Due to Major Causes of Death in US All Races, Both Sexes, 2000



Estimates produced using 2000 Life Tables

# SEER Incidence and Delay Adjusted Incidence Rates<sup>+</sup> All Cancer Sites, By Sex




+ Source: SEER 9 areas. Rates are age-adjusted to the 2000 US standard million population by 5-year age groups. Regression lines and the APCs are calculated using the Joinpoint Regression Program. The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.

\* The APC is significantly different from zero ( $p < 0.05$ ).

Figure I-21



# SEER Incidence and Delay Adjusted Incidence Rates<sup>+</sup> Both Sexes



+ Source: SEER 9 areas. Rates are age-adjusted to the 2000 US standard million population by 5-year age groups. Regression lines and the APCs are calculated using the Joinpoint Regression Program. The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.

\* The APC is significantly different from zero ( $p < 0.05$ ).

Figure I-22

# SEER Incidence and Delay Adjusted Incidence Rates<sup>†</sup> Males





Figure I-23

+ Source: SEER 9 areas. Rates are age-adjusted to the 2000 US standard million population by 5-year age groups. Regression lines and the APCs are calculated using the Joinpoint Regression Program. The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.

\* The APC is significantly different from zero ( $p < 0.05$ ).

# SEER Incidence and Delay Adjusted Incidence Rates<sup>+</sup> Females



+ Source: SEER 9 areas. Rates are age-adjusted to the 2000 US standard million population by 5-year age groups. Regression lines and the APCs are calculated using the Joinpoint Regression Program. The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.  
 \* The APC is significantly different from zero ( $p < 0.05$ ).

Figure I-24